1
|
Wilson IB, Cole MB, Lee Y, Shireman TI, Justice AC, Rahman M. The relationship of age and comorbid conditions to hospital and nursing home days in Medicaid recipients with HIV. AIDS 2024; 38:993-1001. [PMID: 38411618 PMCID: PMC11062810 DOI: 10.1097/qad.0000000000003870] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2023] [Revised: 01/30/2024] [Accepted: 02/12/2024] [Indexed: 02/28/2024]
Abstract
OBJECTIVE To determine how aging impacts healthcare utilization in persons with HIV (PWH) compared with persons without HIV (PWoH). DESIGN Matched case-control study. METHODS We studied Medicaid recipients in the United States, aged 18-64 years, from 2001 to 2012. We matched each of 270 074 PWH to three PWoH by baseline year, age, gender, and zip code. Outcomes were hospital and nursing home days per month (DPM). Comorbid condition groups were cardiovascular disease, diabetes, liver disease, mental health conditions, pulmonary disease, and renal disease. We used linear regression to examine the joint relationships of age and comorbid conditions on the two outcomes, stratified by sex at birth. RESULTS We found small excesses in hospital DPM for PWH compared with PWoH. There were 0.03 and 0.07 extra hospital DPM for female and male individuals, respectively, and no increases with age. In contrast, excess nursing home DPM for PWH compared with PWoH rose linearly with age, peaking at 0.35 extra days for female individuals and 0.4 extra days for male individuals. HIV-associated excess nursing home DPM were greatest for persons with cardiovascular disease, diabetes, mental health conditions, and renal disease. For PWH at age 55 years, this represents an 81% increase in the nursing home DPM for male individuals, and a 110% increase for female individuals, compared PWoH. CONCLUSION Efforts to understand and interrupt this pronounced excess pattern of nursing home DPM among PWH compared with PWoH are needed and may new insights into how HIV and comorbid conditions jointly impact aging with HIV.
Collapse
Affiliation(s)
- Ira B. Wilson
- Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, RI
| | - Megan B. Cole
- Department of Health Law, Policy, & Management, Boston University School of Public Health, Boston, MA
| | - Yoojin Lee
- Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, RI
| | - Theresa I. Shireman
- Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, RI
| | - Amy C. Justice
- Schools of Medicine and Public Health, Yale University; Veterans Affairs Connecticut Healthcare System, New Haven, CT, USA
| | - Momotazur Rahman
- Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, RI
| |
Collapse
|
2
|
Filipkowski AM, Kundu S, Eden SK, Alcorn CW, Justice AC, So-Armah KA, Tindle HA, Wells QS, Beckman JA, Freiberg MS, Aday AW. Association of HIV Infection and Incident Abdominal Aortic Aneurysm Among 143 001 Veterans. Circulation 2023; 148:135-143. [PMID: 37226738 PMCID: PMC10443901 DOI: 10.1161/circulationaha.122.063040] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2022] [Accepted: 05/01/2023] [Indexed: 05/26/2023]
Abstract
BACKGROUND People with HIV (PWH) have an increased risk of cardiovascular disease. Previous cross-sectional data suggest there is a higher prevalence of abdominal aortic aneurysm (AAA) in PWH than in those without HIV. Whether PWH have an increased risk of incident AAA compared with those without HIV is unknown. METHODS We analyzed data among participants without prevalent AAA from the Veterans Aging Cohort Study, a prospective, observational, longitudinal cohort of veterans with HIV matched 1:2 with veterans without HIV infection. We calculated AAA rates by HIV status and assessed the association between HIV infection and incident AAA using Cox proportional hazards models. We defined AAA using the International Classification of Diseases, 9th or 10th revision, or Current Procedural Terminology codes and adjusted all models for demographic characteristics, cardiovascular disease risk factors, and substance use. Secondary analyses examined the association between time-varying CD4+ T-cell count or HIV viral load and incident AAA. RESULTS Among 143 001 participants (43 766 with HIV), over a median follow-up of 8.7 years, there were 2431 incident AAA events (26.4% among PWH). Rates of incident AAA per 1000 person-years were similar among PWH (2.0 [95% CI, 1.9-2.2]) and people without HIV (2.2 [95% CI, 2.1-2.3]). There was no evidence that HIV infection increased the risk of incident AAA compared with no HIV infection (adjusted hazard ratio, 1.02 [95% CI, 0.92-1.13]). In adjusted analyses with time-varying CD4+ T-cell counts or HIV viral load, PWH with CD4+ T-cell counts <200 cells/mm3 (adjusted hazard ratio, 1.29 [95% CI, 1.02-1.65]) or HIV viral load ≥500 copies/mL (adjusted hazard ratio, 1.29 [95% CI, 1.09-1.52]) had an increased risk of AAA compared with those without HIV. CONCLUSIONS HIV infection is associated with an increased risk of AAA among those with low CD4+ T-cell counts or elevated HIV viral load over time.
Collapse
Affiliation(s)
| | - Suman Kundu
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Svetlana K. Eden
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Charles W. Alcorn
- University of Pittsburgh School of Public Health, Pittsburgh, PA, USA
| | - Amy C. Justice
- Veterans Affairs Connecticut Healthcare System, CT, USA
- Department of Internal Medicine, Yale School of Medicine, West Haven, CT, USA
| | - Kaku A. So-Armah
- Division of General Internal Medicine, Boston University School of Medicine, Boston, MA, USA
| | - Hilary A. Tindle
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Quinn S. Wells
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Joshua A. Beckman
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Matthew S. Freiberg
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
| | - Aaron W. Aday
- Vanderbilt Translational and Clinical Cardiovascular Research Center, Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| |
Collapse
|
3
|
Smith CM, Kennedy JL, Evans ME, Person MK, Haverkate R, Apostolou A. Mental Illness in Adults With HIV and HCV Infection: Indian Health Service, 2001-2020. Am J Prev Med 2022; 63:e77-e86. [PMID: 35589441 PMCID: PMC9887638 DOI: 10.1016/j.amepre.2022.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Revised: 02/20/2022] [Accepted: 03/21/2022] [Indexed: 02/02/2023]
Abstract
INTRODUCTION Mental health disorders (MHDs) and substance use disorders (SUDs) in people living with HIV, hepatitis C virus (HCV) infection, and HIV/HCV coinfection are common and result in significant morbidity. However, there are no national prevalence estimates of these comorbidities in American Indian and Alaska Native (AI/AN) adults with HIV, HCV infection, or HIV/HCV coinfection. This study estimates the prevalence of MHD and SUD diagnoses in AI/AN adults diagnosed with HIV, HCV infection, or HIV/HCV coinfection within the Indian Health Service (IHS). METHODS In 2021, a cross-sectional study using data from the National Patient Information Reporting System was completed to identify MHD or SUD diagnoses in AI/AN adults with HIV, HCV infection, or HIV/HCV coinfection within the IHS during fiscal years 2001‒2020. Logistic regression was used to compare the odds of MHD or SUD diagnoses, adjusting for age and sex. RESULTS Of AI/AN adults diagnosed with HIV, hepatitis C virus infection, or HIV/HCV coinfection, the period prevalence of MHD or SUD diagnoses ranged from 57.2% to 81.1%. Adjusting for age and sex, individuals with HCV infection had higher odds of receiving a MHD diagnosis (AOR=1.57; 95% CI=1.47, 1.68) or SUD diagnosis (AOR=3.40; 95% CI=3.18, 3.65) than those with HIV, and individuals with HIV/HCV coinfection had higher odds of receiving a MHD diagnosis (AOR=1.60; 95% CI=1.35, 1.89) or SUD diagnosis (AOR=2.81; 95% CI=2.32, 3.41) than those with HIV. CONCLUSIONS MHD and SUD diagnoses were common in AI/AN adults diagnosed with HIV, HCV infection, or HIV/HCV coinfection, highlighting the need for culturally appropriate screening and treatment programs sensitive to the diverse strengths of AI/AN populations and structural challenges they endure.
Collapse
Affiliation(s)
- Colin M Smith
- Department of Medicine, Duke University Medical Center, Durham, North Carolina; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina; Indian Health Service, Rockville, Maryland.
| | - Jordan L Kennedy
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Mary E Evans
- Division of Global HIV and TB, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Marissa K Person
- Division of High-Consequence Pathogens and Pathology, Centers for Disease Control and Prevention, Atlanta, Georgia
| | | | | |
Collapse
|
4
|
Dias JP, Piggott DA, Sun J, Wehbeh L, Garza J, Abraham A, Astemborski J, Moseley KF, Basaria S, Varadhan R, Brown TT. SHBG, Bone Mineral Density, and Physical Function Among Injection Drug Users With and Without HIV and HCV. J Clin Endocrinol Metab 2022; 107:e2971-e2981. [PMID: 35293996 PMCID: PMC9202730 DOI: 10.1210/clinem/dgac144] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/14/2021] [Indexed: 11/19/2022]
Abstract
CONTEXT Sex hormone-binding globulin (SHBG) is a glycoprotein that regulates the bioavailability of sex hormones and is higher in people with HIV (PWH) and hepatitis C virus (HCV). SHBG is associated with aging-related diseases, including osteoporosis and frailty in the general population. However, the relationship between SHBG concentration and bone mineral density (BMD) and physical function among PWH and HCV is unclear. OBJECTIVE This study aimed to evaluate the association between chronic infection with HIV and HCV and SHBG, and to assess the relationship of circulating SHBG concentrations with low BMD, physical function impairment, and frailty. METHODS A cross-sectional study was conducted of 278 HCV-exposed (HCV antibody positive) adults enrolled with and without HIV and HCV from the AIDS Linked to the IntraVenous Experience cohort study into 4 groups: HCV-/HIV-, HCV-/HIV+, HCV+/HIV-, and HCV+/HIV+. We evaluated the association between SHBG concentrations and grip strength, gait speed, Short Physical Performance Battery score, frailty (Fried Frailty Phenotype), and BMD (lumbar spine, total hip, and femoral neck T-score) by using adjusted multivariable regression stratified by sex. RESULTS SHBG concentrations were higher in women, in those with HIV RNA greater than 400 copies/mL (P = .02) and HCV RNA greater than 15 IU/mL (P < .001). In adjusted models, higher SHBG concentrations among women were statistically significantly associated with lower grip strength (-0.43 [95% CI, -0.77 to -0.081] kg/10 nmol/L, P < .05), higher odds of frailty (odds ratio, 1.49 [95% CI, 1.07 to 2.08], P < .05), and lower T-scores at the lumbar spine (-0.070 [95% CI, -0.15 to -0.001] SD/10 nmol/L T-score BMD, P < .05). Similar associations were not observed among men. CONCLUSION Higher SHBG concentrations are associated with the presence of HIV and HCV viremia. Among women, but not men, higher SHBG concentrations were associated with lower grip strength, higher odds of frailty, and lower lumbar spine BMD. The underlying mechanisms of these associations require further investigation.
Collapse
Affiliation(s)
- Jenny Pena Dias
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Damani A Piggott
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Jing Sun
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Leen Wehbeh
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Joshua Garza
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Alison Abraham
- Department of Epidemiology Johns Hopkins Bloomberg School of Public Health; Department of Epidemiology, School of Public Health and Department of Ophthalmology, School of Medicine, University of Colorado Anschutz Medical Campus, Colorado, USA
| | - Jacquie Astemborski
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
| | - Kendall F Moseley
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
| | - Shehzad Basaria
- Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Ravi Varadhan
- Department of Oncology; Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, Maryland, USA
| | - Todd T Brown
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA
- Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA
| |
Collapse
|
5
|
Patients, Social Workers, and Pharmacists' Perceptions of Barriers to Providing HIV Care in Community Pharmacies in the United States. PHARMACY 2021; 9:pharmacy9040178. [PMID: 34842829 PMCID: PMC8628938 DOI: 10.3390/pharmacy9040178] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 10/26/2021] [Accepted: 10/28/2021] [Indexed: 11/30/2022] Open
Abstract
Retaining people living with HIV (PLWH) in clinical care is a global priority to end the HIV epidemic. Community pharmacies in the United States have structural influences on the success or failure of retention in HIV care by supporting patients’ complex needs. However, to date, barriers to retention in care in the community pharmacy setting have not been examined beyond pharmacy services of medication therapy management. We utilized the patient-centered medical home model to examine the barriers to HIV care in the community pharmacy setting. We utilized semi-structured interviews to collect data from 15 participants: five PLWH, five community pharmacists, and five social workers from a midwestern state. Interview data were transcribed and analyzed using directed content analysis. Four key themes emerged regarding the barriers that impact utilization of community pharmacy services by PLWH: the perception of the role of community pharmacists in HIV care, perceptions of pharmacists’ HIV knowledge, perceptions of pharmacy operation and services, and negative experiences within the community pharmacy space. Participants’ perceptions of solutions for improving HIV care in the community pharmacy focused on improving the relationship between pharmacists and patients, ensuring that the community pharmacy is a private and safe space for patients, and having a diverse pharmacy staff that is equipped to take care of the diverse and marginalized HIV population, such as transgender people.
Collapse
|
6
|
Freiberg MS, Duncan MS, Alcorn C, Chang CH, Kundu S, Mumpuni A, Smith EK, Loch S, Bedigian A, Vittinghoff E, So‐Armah K, Hsue PY, Justice AC, Tseng ZH. HIV Infection and the Risk of World Health Organization-Defined Sudden Cardiac Death. J Am Heart Assoc 2021; 10:e021268. [PMID: 34493058 PMCID: PMC8649505 DOI: 10.1161/jaha.121.021268] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2021] [Accepted: 07/09/2021] [Indexed: 12/04/2022]
Abstract
Background People living with HIV have higher sudden cardiac death (SCD) rates compared with the general population. Whether HIV infection is an independent SCD risk factor is unclear. Methods and Results This study evaluated participants from the Veterans Aging Cohort Study, an observational, longitudinal cohort of veterans with and without HIV infection matched 1:2 on age, sex, race/ethnicity, and clinical site. Baseline for this study was a participant's first clinical visit on or after April 1, 2003. Participants were followed through December 31, 2014. Using Cox proportional hazards regression, we assessed whether HIV infection, CD4 cell counts, and/or HIV viral load were associated with World Health Organization (WHO)-defined SCD risk. Among 144 336 participants (30% people living with HIV), the mean (SD) baseline age was 50.0 years (10.6 years), 97% were men, and 47% were of Black race. During follow-up (median, 9.0 years), 3035 SCDs occurred. HIV infection was associated with increased SCD risk (hazard ratio [HR], 1.14; 95% CI, 1.04-1.25), adjusting for possible confounders. In analyses with time-varying CD4 and HIV viral load, people living with HIV with CD4 counts <200 cells/mm3 (HR, 1.57; 95% CI, 1.28-1.92) or viral load >500 copies/mL (HR, 1.70; 95% CI, 1.46-1.98) had increased SCD risk versus veterans without HIV. In contrast, people living with HIV who had CD4 cell counts >500 cells/mm3 (HR, 1.03; 95% CI, 0.90-1.18) or HIV viral load <500 copies/mL (HR, 0.97; 95% CI, 0.87-1.09) were not at increased SCD risk. Conclusions HIV infection is associated with increased risk of WHO-defined SCD among those with elevated HIV viral load or low CD4 cell counts.
Collapse
Affiliation(s)
- Matthew S. Freiberg
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTN
- Geriatric Research Education and Clinical Centers (GRECC)Veterans Affairs Tennessee Valley Healthcare SystemNashvilleTN
- Department of MedicineVanderbilt University Medical CenterNashvilleTN
- Yale School of Public HealthNew HavenCT
| | - Meredith S. Duncan
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTN
- Department of BiostatisticsUniversity of KentuckyLexingtonKY
| | - Charles Alcorn
- Department of BiostatisticsGraduate School of Public HealthUniversity of PittsburghPA
| | - Chung‐Chou H. Chang
- Department of MedicineUniversity of Pittsburgh School of MedicinePittsburghPA
| | - Suman Kundu
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTN
| | - Asri Mumpuni
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTN
- Vanderbilt Institute for Clinical and Translational ResearchVanderbilt University Medical CenterNashvilleTN
| | - Emily K. Smith
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTN
| | - Sarah Loch
- Division of Cardiovascular MedicineVanderbilt University Medical CenterNashvilleTN
- Vanderbilt Center for Child Health PolicyVanderbilt University Medical CenterNashvilleTN
| | | | - Eric Vittinghoff
- Department of Epidemiology and BiostatisticsUniversity of California at San FranciscoCA
| | - Kaku So‐Armah
- Division of General Internal MedicineBoston UniversityBostonMA
| | - Priscilla Y. Hsue
- Division of CardiologyUniversity of California San FranciscoSan FranciscoCA
| | - Amy C. Justice
- Veterans Affairs Connecticut Health Care SystemWest Haven Veterans Administration Medical CenterWest HavenCT
- Department of MedicineYale School of MedicineNew HavenCT
| | - Zian H. Tseng
- Cardiac Electrophysiology Section, Division of CardiologyUniversity of California San FranciscoSan FranciscoCA
| |
Collapse
|
7
|
Dias JP, Haberlen SA, Dobs AS, Lake JE, Palella FJ, Kingsley LA, Price JC, Basaria S, Varadhan R, Margolick JB, Thio CL, Brown TT. Longitudinal Changes in Sex Hormone-Binding Globulin in Men With HIV. J Acquir Immune Defic Syndr 2021; 87:1178-1186. [PMID: 33990494 PMCID: PMC8263509 DOI: 10.1097/qai.0000000000002723] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2020] [Accepted: 03/29/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND Sex hormone-binding globulin (SHBG) is a glycoprotein that regulates sex hormone bioavailability and increases with age in the general population. SHBG concentrations are higher in people with HIV, a population in whom accelerated aging has been hypothesized. It is unclear whether longitudinal changes in SHBG increase over time and differ by HIV serostatus. METHODS In a longitudinal study, SHBG was measured in 182 men with HIV (MWH) and 267 men without HIV (seronegative) from the Multicenter AIDS Cohort Study and matched for age, race, site, and time, with ≥2 SHBG serum samples over the 10 years after HAART initiation. Multivariable linear mixed-effects regression models were used to evaluate whether log-transformed SHBG [ln(SHBG)] and its rate of change differed by HIV serostatus. RESULTS At baseline, the mean age in MWH was similar to that in HIV-seronegative men (51 ± 5 vs 49 ± 6 years). However, SHBG mean values were higher in MWH compared with those in HIV-seronegative men (65.6 ± 48.8 vs. 45.4 ± 22 nmol/L, P < 0.001). In a fully adjusted model, SHBG increased over time and at a faster rate in MWH compared with that in HIV-seronegative men: [2.0%/year (95% CI: 1.4 to 2.7) vs 1.3%/year (95% CI: 0.8 to 1.8), respectively, P = 0.038]. Among MWH, higher SHBG concentrations were significantly associated with lower CD4+ T-cell count [β= -0.02 (95% CI: -0.03 to -0.0002), P < 0.05], fewer cumulative years on zidovudine [β = -0.027 (95% CI: -0.045 to -0.009), P < 0.001], and greater cumulative years on nonnucleoside reverse transcriptase inhibitors drugs [β = 0.022 (95% CI: 0.0006 to 0.04), P < 0.05]. CONCLUSIONS Aging-related increases in SHBG were faster in MWH compared with those in HIV-seronegative men and were related to poorer immunologic status and antiretroviral medication exposure. The mechanisms and consequences of these findings require further investigation.
Collapse
Affiliation(s)
- Jenny Pena Dias
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, United States
| | - Sabina A Haberlen
- Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
| | - Adrian S. Dobs
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, United States
| | - Jordan E Lake
- Division of Infectious Diseases, McGovern School of Medicine, Houston, TX, USA
| | - Frank J. Palella
- Division of Infectious Disease, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States
| | - Lawrence A. Kingsley
- Department of Infectious Diseases and Microbiology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
| | - Jennifer C. Price
- Division of Gastroenterology and Hepatology, Department of Medicine, University of California, San Francisco, San Francisco, California
| | - Shehzad Basaria
- Section on Men’s Health, Aging and Metabolism, Brigham and Women’s Hospital Harvard Medical School, Boston, MA, United States
| | - Ravi Varadhan
- Department of Oncology; Biostatistics and Bioinformatics, Johns Hopkins University, Baltimore, MD, United States
| | - Joseph B. Margolick
- Department of Molecular Microbiology and Immunology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, United States
| | - Chloe L Thio
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, United States
| | - Todd T. Brown
- Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, MD, United States
| |
Collapse
|
8
|
Abstract
PURPOSE OF REVIEW With the progressive aging of populations of people with HIV (PWH), multimorbidity is increasing. Multimorbidity patterns, that is groups of comorbidities that are likely to co-occur, may suggest shared causes or common risk factors. We review the literature regarding multimorbidity patterns identified with data-driven approaches and discuss the methodology and potential implications of the findings. RECENT FINDINGS Despite the substantial heterogeneity in the methods used to identify multimorbidity patterns, patterns of mental health problems, cardiovascular diseases, metabolic disorders and musculoskeletal problems are consistently reported in the general population, with patterns of mental health problems, cardiovascular diseases or metabolic disorders commonly reported in PWH. In addition to these, patterns of lifestyle-related comorbidities, such as sexually transmitted diseases, substance use (alcohol, recreational drugs and tobacco smoking) or their complications, seem to occur among PWH. SUMMARY Multimorbidity patterns could inform the development of appropriate guidelines for the prevention, monitoring and management of multiple comorbidities in PWH. They can also help to generate new hypotheses on the causes underlying previously known and unknown associations between comorbidities and facilitate the identification of risk factors and biomarkers for specific patterns.
Collapse
|
9
|
Yang X, Zhang J, Chen S, Weissman S, Olatosi B, Li X. Comorbidity patterns among people living with HIV: a hierarchical clustering approach through integrated electronic health records data in South Carolina. AIDS Care 2020; 33:594-606. [PMID: 33172284 DOI: 10.1080/09540121.2020.1844864] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
Comorbidity among people living with HIV (PLWH) is understudied although identifying its patterns and socio-demographic predictors would be beneficial for comorbidity management. Using electronic health records (EHR) data, 8,490 PLWH diagnosed between January 2005 and December 2016 in South Carolina were included in the current study. An initial list of 86 individual diagnoses of chronic conditions was extracted in the EHR data. After grouping individual diagnoses with a pathophysiological similarity, 24 diagnosis groups were generated. Hierarchical cluster analysis was applied to these 24 diagnosis groups and yielded four comorbidity clusters: "substance use and mental disorder" (e.g., alcohol use, depression, and illicit drug use); "metabolic disorder" (e.g., hypothyroidism, diabetes, hypertension, and chronic kidney disease); "liver disease and cancer" (e.g., hepatitis B, chronic liver disease, and non-AIDS defining cancers); and "cerebrovascular disease" (e.g., stroke and dementia). Multivariable logistic regression was conducted to investigate the association between socio-demographic factors and multimorbidity (defined as concurrence of ≥ 2 comorbidity clusters). The multivariable logistic regression showed that age, gender, transmission risk, race, initial CD4 counts, and viral load were significant factors associated with multimorbidity. The results suggested the importance of integrated clinical care that addresses the complexities of multiple, and potentially interacting comorbidities among PLWH.
Collapse
Affiliation(s)
- Xueying Yang
- South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.,Department of Health Promotion, Education and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| | - Jiajia Zhang
- South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.,Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| | - Shujie Chen
- South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.,Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| | - Sharon Weissman
- Department of Internal Medicine, School of Medicine, University of South Carolina, Columbia, SC, USA
| | - Bankole Olatosi
- South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.,Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| | - Xiaoming Li
- South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA.,Department of Health Promotion, Education and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, SC, USA
| |
Collapse
|
10
|
van Boemmel-Wegmann S, Lo Re V, Park H. Early Treatment Uptake and Cost Burden of Hepatitis C Therapies Among Newly Diagnosed Hepatitis C Patients with a Particular Focus on HIV Coinfection. Dig Dis Sci 2020; 65:3159-3174. [PMID: 31938995 PMCID: PMC7358122 DOI: 10.1007/s10620-019-06037-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2019] [Accepted: 12/30/2019] [Indexed: 12/14/2022]
Abstract
BACKGROUND Despite the high efficacy and safety associated with direct-acting antivirals (DAAs), access to HCV treatment has been frequently restricted because of the high DAA drug costs. OBJECTIVES To (1) compare HCV treatment initiation rates between HCV monoinfected and HCV/HIV coinfected patients before (pre-DAA period) and after (post-DAA period) all-oral DAAs became available; and to (2) estimate the HCV treatment costs for payers and patients. RESEARCH DESIGN AND METHODS A retrospective analysis of the MarketScan® Databases (2009-2016) was conducted for newly diagnosed HCV patients. Multivariable logistic regression was used to estimate the odds ratio (OR) of initiating HCV treatments during the pre-DAA and post-DAA periods. Kruskal-Wallis test was used to compare drug costs for dual, triple and all-oral therapies. RESULTS A total of 15,063 HCV patients [382 (2.5%) HIV coinfected] in the pre-DAA period and 14,896 [429 (2.9%) HIV coinfected] in the post-DAA period were included. HCV/HIV coinfected patients had lower odds of HCV treatment uptake compared to HCV monoinfected patients during the pre-DAA period [OR, 0.59; 95% confidence interval (CI), 0.45-0.78], but no significant difference in odds of HCV treatment uptake was observed during the post-DAA period (OR, 1.08; 95% CI, 0.87-1.33). From 2009 to 2016, average payers' treatment costs (dual, $20,820; all-oral DAAs, $99,661; p < 0.001) as well as average patients' copayments (dual, $593; all-oral DAAs $933; p < 0.001) increased significantly. CONCLUSIONS HCV treatment initiation rates increased, especially among HCV/HIV coinfected patients, from the pre-DAA to the post-DAA period. However, payers' expenditures per course of therapy saw an almost fivefold increase and patients' copayments increased by 55%.
Collapse
Affiliation(s)
- Sascha van Boemmel-Wegmann
- Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, HPNP Building Room 3325, 1225 Center Drive, Gainesville, FL, 32610, USA
| | - Vincent Lo Re
- Division of Infectious Diseases, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Haesuk Park
- Department of Pharmaceutical Outcomes and Policy, University of Florida College of Pharmacy, HPNP Building Room 3325, 1225 Center Drive, Gainesville, FL, 32610, USA.
| |
Collapse
|
11
|
Gordon KS, Manhapra A, Crystal S, Dziura J, Edelman EJ, Skanderson M, Kerns RD, Justice AC, Tate J, Becker WC. All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factors. Drug Alcohol Depend 2020; 216:108291. [PMID: 33011662 PMCID: PMC7644145 DOI: 10.1016/j.drugalcdep.2020.108291] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2020] [Revised: 08/28/2020] [Accepted: 09/04/2020] [Indexed: 12/31/2022]
Abstract
BACKGROUND While the relationship between long-term opioid therapy (LTOT) dose and overdose is well-established, LTOT's association with all-cause mortality is less understood, especially among people living with HIV (PLWH). There is also limited information regarding the association of LTOT cessation or interruption with mortality. METHODS Among PLWH and matched uninfected male veterans in care, we identified those who initiated LTOT. Using time-updated cox regression, we examined the association between all-cause mortality, unnatural death, and overdose, and opioid use categorized as 1-20 (reference group), 21-50, 51-90, and ≥ 91 mg morphine equivalent daily dose (MEDD). RESULTS There were 22,996 patients on LTOT, 6,578 (29 %) PLWH and 16,418 (71 %) uninfected. Among 5,222 (23 %) deaths, 12 % were unnatural deaths and 6 % overdoses. MEDD was associated with risk of all 3 outcomes; compared to patients on 1-20 mg MEDD, adjusted risk for all-cause mortality monotonically increased (Hazard Ratios (HR) [95 % CI] for 21-50 mg MEDD = 1.36 [1.21, 1.52], 51-90 mg MEDD = 2.06 [1.82, 2.35], and ≥ 91 mg MEDD = 3.03 [2.71, 3.39]). Similar results were seen in models stratified by HIV. LTOT interruption was also associated with all-cause, unnatural, and overdose mortality (HR [95 % CI] 2.30 [2.09, 2.53], 1.47 [1.13, 1.91] and 1.52 [1.04, 2.23], respectively). CONCLUSIONS Among PLWH and uninfected patients on LTOT we observed a strong dose-response relationship with all 3 mortality outcomes. Opioid risk mitigation approaches should be expanded to address the potential effects of higher dose on all-cause mortality in addition to unnatural and overdose fatalities.
Collapse
Affiliation(s)
- K S Gordon
- VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States.
| | - A Manhapra
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States; Integrative Pain Recovery Service, Hampton VA Medical Center, Hampton, VA, United States; Departments of Physical Medicine & Rehabilitation and Psychiatry, Eastern Virginia Medical School, Norfolk, VA, United States
| | - S Crystal
- Rutgers University, New Brunswick, NJ, United States
| | - J Dziura
- Yale School of Public Health, New Haven, CT, United States
| | - E J Edelman
- Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States
| | - M Skanderson
- VA Connecticut Healthcare System, West Haven, CT, United States
| | - R D Kerns
- Department of Psychiatry, Yale School of Medicine, New Haven, CT, United States; Department of Neurology, Yale School of Medicine, New Haven, CT, United States
| | - A C Justice
- VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States; Yale School of Public Health, New Haven, CT, United States
| | - J Tate
- VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States
| | - W C Becker
- VA Connecticut Healthcare System, West Haven, CT, United States; Department of Internal Medicine, Yale School of Medicine, New Haven, CT, United States
| |
Collapse
|
12
|
Zola CE, Duncan MS, So-Armah K, Crothers KA, Butt AA, Gibert CL, Kim JWW, Lim JK, Re VL, Tindle HA, Freiberg MS, Brittain EL. HIV- and HCV-specific markers and echocardiographic pulmonary artery systolic pressure among United States veterans. Sci Rep 2020; 10:18729. [PMID: 33127959 PMCID: PMC7599329 DOI: 10.1038/s41598-020-75290-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Accepted: 10/08/2020] [Indexed: 01/05/2023] Open
Abstract
Hepatitis C virus (HCV) may increase pulmonary hypertension (PH) risk among people living with HIV (PLWH). Prior studies on this topic have been relatively small and examined selected populations. We determine whether HIV/HCV coinfection is associated with higher pulmonary artery systolic pressure (PASP) and prevalent echocardiographic PH. We performed a cross-sectional analysis of 6032 (16% HIV/HCV coinfected) Veterans Aging Cohort Study participants enrolled 4/1/2003-9/30/2012 with echocardiographic PASP measures. We performed multiple linear and logistic regression analyses to determine whether HIV/HCV mono- or co-infection were associated with PASP and PH compared to uninfected individuals. Individuals with HIV/HCV coinfection displayed a higher PASP than uninfected individuals ([Formula: see text]=1.10, 95% CI 0.01, 2.20) but there was no association between HIV/HCV coinfection and prevalent PH. Subset analyses examined HIV and HCV disease severity markers separately and jointly. Among PLWH, HCV coinfection ([Formula: see text]=1.47, 95% CI 0.26, 2.67) and CD4 + cell count ([Formula: see text]= - 0.68, 95% CI - 1.10, - 0.27), but not HIV viral load nor ART regimen, were associated with PASP. Among people with HCV, neither HIV coinfection nor HCV biomarkers were associated with PASP. Among US veterans referred for echocardiography, HIV/HCV coinfection was not associated with a clinically significant elevation in pulmonary pressure. Lower absolute CD4 + T-cell count was inversely associated with PASP which warrants further investigation in prospective studies.
Collapse
Affiliation(s)
- Courtney E Zola
- Division of Infectious Disease, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Meredith S Duncan
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 300A, Nashville, TN, 37203, USA
| | - Kaku So-Armah
- School of Medicine, Section of General Internal Medicine, Boston University, Boston, MA, USA
| | - Kristina A Crothers
- Department of Medicine, University of Washington School of Medicine, Seattle, WA, USA
| | - Adeel A Butt
- VA Pittsburgh Healthcare System, Pittsburgh, PA, USA
- Weill Cornell Medical College, New York, NY, USA
- Weill Cornell Medical College, Doha, Qatar
| | - Cynthia L Gibert
- Department of Medicine, George Washington University, Washington, DC, USA
| | - Joon Woo W Kim
- Department of Medicine, Icahn School of Medicine At Mt. Sinai, James J. Peters VA Medical Center, New York City, NY, USA
| | - Joseph K Lim
- Department of Medicine, Yale University School of Medicine, New Haven, CT, USA
| | - Vincent Lo Re
- Division of Infectious Disease, Department of Medicine and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Hilary A Tindle
- Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Matthew S Freiberg
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 300A, Nashville, TN, 37203, USA
- Geriatric Research Education and Clinical Centers (GRECC), Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
| | - Evan L Brittain
- Division of Cardiovascular Medicine, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 300A, Nashville, TN, 37203, USA.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
| |
Collapse
|
13
|
Machado SM, Vigani AG, Leite AG, Diaz ACM, Ferreira PRA, Carnaúba-Júnior D, Tenore SB, Brandão-Mello CE, Gonzalez MP, Siroma F, Prado KD, Nunes DV, Lisboa-Neto G, Pinho JRR, Malta FM, Azevedo RS, Witkin SS, Mendes-Correa MC. Effectiveness of direct-acting antivirals for hepatitis C virus infection in hepatitis C/HIV coinfected individuals: A multicenter study. Medicine (Baltimore) 2020; 99:e21270. [PMID: 32791706 PMCID: PMC7387014 DOI: 10.1097/md.0000000000021270] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
In a hepatitis C virus (HCV)/HIV-positive Brazilian cohort, evaluate the safety and efficacy of HCV DAAs, the frequency of resistance substitutions in the HCV NS5A and NS5B genes and identify predictors of treatment failure.Retrospective multicenter study of HCV/HIV patients treated with sofosbuvir (SOF)-based regimens at 10 reference centers in Brazil.Clinical and virological data were collected. Genetic diversity in the NS5A and NS5B genes was assessed by direct nucleotide sequencing. The primary outcome was sustained virological response (SVR) 12 weeks after DAA completion.Of 643 HCV/HIV patients analyzed, 74.7% were male, median CD4+ T cell count was 617 cells/mm, 90% had an undetectable HIV viral load. HCV genotype 1 was detected in 80.2%, and 60% were taking at least 1 medication other than antiretroviral drugs during their DAA therapy. Cirrhosis was present in 42%. An SOF/daclatasvir (DCV) regimen was used in most patients (98%). The frequency of NS5A polymorphisms associated with clinically relevant resistance to DCV was 2%; no relevant NS5B variants were identified. The SVR12 rate was 92.8% in an intention to treat (ITT) analysis and 96% in a modified ITT (m-ITT) analysis. AE occurred in 1.6% of patients. By multivariate analysis, therapeutic failure was associated, in the m-ITT analysis, with concomitant use of anticonvulsant drugs (P = .001), age (P = .04), and female gender (P = .04).SOF/DCV regimens were associated with a high SVR rate in an HCV/HIV population. The use of concurrent anticonvulsant drugs and DAAs decreases the chances of achieving an SVR.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | | | | | | | | | - João Renato R. Pinho
- University of São Paulo School of Medicine, São Paulo
- LIM 07, Institute of Tropical Medicine, São Paulo
| | | | | | - Steven S. Witkin
- Department of Obstetrics and Gynecology, Weill Cornell Medicine, New York, NY
- LIM 52, Institute of Tropical Medicine, São Paulo
| | | |
Collapse
|
14
|
Yang X, Li X, Qiao S. Patterns of comorbidity and sociodemographic and psychosocial correlates among people living with HIV in South Carolina, USA. HIV Med 2020; 21:205-216. [DOI: 10.1111/hiv.12812] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2019] [Revised: 09/05/2019] [Accepted: 09/17/2019] [Indexed: 12/25/2022]
Affiliation(s)
- X Yang
- Department of Health Promotion, Education, and Behavior South Carolina SmartState Center for Healthcare Quality (CHQ) University of South Carolina Arnold School of Public Health Columbia SC USA
| | - X Li
- Department of Health Promotion, Education, and Behavior South Carolina SmartState Center for Healthcare Quality (CHQ) University of South Carolina Arnold School of Public Health Columbia SC USA
| | - S Qiao
- Department of Health Promotion, Education, and Behavior South Carolina SmartState Center for Healthcare Quality (CHQ) University of South Carolina Arnold School of Public Health Columbia SC USA
| |
Collapse
|
15
|
McGrew K, Homco J, Garwe T, Dao HD, Williams MB, Drevets DA, Jafarzadeh SR, Zhao YD, Carabin H. Validity of International Classification of Diseases codes in identifying illicit drug use target conditions using medical record data as a reference standard: A systematic review. Drug Alcohol Depend 2020; 208:107825. [PMID: 31982637 PMCID: PMC9533471 DOI: 10.1016/j.drugalcdep.2019.107825] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/02/2019] [Revised: 12/08/2019] [Accepted: 12/11/2019] [Indexed: 12/31/2022]
Abstract
BACKGROUND The twenty-first century opioid crisis has spurred interest in using International Classification of Diseases (ICD) code algorithms to identify patients using illicit drugs from administrative healthcare data. We conducted a systematic review of studies that validated ICD code algorithms for illicit drug use against a reference standard of medical record data. METHODS Systematic searches of MEDLINE, EMBASE, PsycINFO, and Web of Science were conducted for studies published between 1980 and 2018 in English, French, Italian, or Spanish. We included validation studies of ICD-9 or ICD-10 code algorithms for an illicit drug use target condition (e.g., illicit drug use, abuse, or dependence (UAD), illicit drug use-related complications) given the sensitivity or specificity was reported or could be calculated. Bias was assessed with the Quality Assessment of Diagnostic Accuracy Studies Version 2 (QUADAS-2) tool. RESULTS Six of the 1210 articles identified met the inclusion criteria. For validation studies of broad UAD (n = 4), the specificity was nearly perfect, but the sensitivity ranged from 47% to 83%, with higher sensitivities tending to occur in higher prevalence populations. For validation studies of injection drug use (IDU)-associated infective endocarditis (n = 2), sensitivity and specificity were poor due to the lack of an ICD code for IDU. For all six studies, the risk of bias for the QUADAS-2 "reference standard" and "flow/timing domains" was scored as "unclear" due to insufficient reporting. CONCLUSIONS Few studies have validated ICD code algorithms for illicit drug use target conditions, and available evidence is challenging to interpret due to inadequate reporting. PROSPERO Registration: CRD42019118401.
Collapse
Affiliation(s)
- Kaitlin McGrew
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States,Corresponding author: Kaitlin McGrew, 801 NE 13th St, Room 309, Oklahoma City, Oklahoma 73104, (405) 229-8568,
| | - Juell Homco
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States,Department of Medical Informatics, OU-TU School of Community Medicine, Tulsa, Oklahoma, United States
| | - Tabitha Garwe
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
| | - Hanh Dung Dao
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
| | - Mary B. Williams
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States,Department of Family and Community Medicine, OU-TU School of Community Medicine, Tulsa, Oklahoma, United States
| | - Douglas A. Drevets
- Department of Internal Medicine- Infectious Diseases, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States,Medical Services, Department of Veterans Affairs Medical Center, Oklahoma City, Oklahoma, United States
| | - S. Reza Jafarzadeh
- Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, United States
| | - Yan Daniel Zhao
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States.
| | - Hélène Carabin
- Department of Biostatistics & Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States; Département de pathologie et de microbiologie, Faculté de Médecine vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec, Canada; Département de médecine sociale et préventive, École de Santé Publique, Université de Montréal, Montréal, Québec, Canada; Centre de Recherche en Santé Publique (CReSP), Université de Montréal, Montréal, Québec, Canada.
| |
Collapse
|
16
|
Giacometti LL, Barker JM. Comorbid HIV infection and alcohol use disorders: Converging glutamatergic and dopaminergic mechanisms underlying neurocognitive dysfunction. Brain Res 2019; 1723:146390. [PMID: 31421128 PMCID: PMC6766419 DOI: 10.1016/j.brainres.2019.146390] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Revised: 08/02/2019] [Accepted: 08/13/2019] [Indexed: 10/26/2022]
Abstract
Alcohol use disorders (AUDs) are highly comorbid with human immunodeficiency virus (HIV) infection, occurring at nearly twice the rate in HIV positive individuals as in the general population. Individuals with HIV who consume alcohol show worse long-term prognoses and may be at elevated risk for the development of HIV-associated neurocognitive disorders. The direction of this relationship is unclear, and likely multifactorial. Chronic alcohol exposure and HIV infection independently promote cognitive dysfunction and further may interact to exacerbate neurocognitive deficits through effects on common targets, including corticostriatal glutamate and dopamine neurotransmission. Additionally, drug and alcohol use is likely to reduce treatment adherence, potentially resulting in accelerated disease progression and subsequent neurocognitive impairment. The development of neurocognitive impairments may further reduce cognitive control over behavior, resulting in escalating alcohol use. This review will examine the complex relationship between HIV infection and alcohol use, highlighting impacts on dopamine and glutamate systems by which alcohol use and HIV act independently and in tandem to alter corticostriatal circuit structure and function to dysregulate cognitive function.
Collapse
Affiliation(s)
- Laura L Giacometti
- Department of Pharmacology and Physiology, Drexel University College of Medicine, United States
| | - Jacqueline M Barker
- Department of Pharmacology and Physiology, Drexel University College of Medicine, United States.
| |
Collapse
|
17
|
Liver stiffness and fibrosis-4 alone better predict liver events compared with aspartate aminotransferase to platelet ratio index in a cohort of human immunodeficiency virus and hepatitis C virus co-infected patients from ANRS CO13 HEPAVIH cohort. Eur J Gastroenterol Hepatol 2019; 31:1387-1396. [PMID: 31033848 DOI: 10.1097/meg.0000000000001408] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
OBJECTIVES HIV/hepatitis C virus (HCV) co-infection leads to major complications, and noninvasive markers developed to stage liver fibrosis could be used as prognostic markers. We aimed to compare the performances of liver stiffness (LS), fibrosis-4 (FIB-4), and aspartate aminotransferase to platelet ratio index (APRI) to predict liver-related events in HIV/HCV co-infected patients. PATIENTS AND METHODS HIV/HCV co-infected patients from the ANRS CO13 HEPAVIH cohort were included if they had LS, FIB-4, and APRI measurements done in a window of 3 months. Primary outcome was the time between inclusion and occurrence of a liver-related event. Univariable and multivariable Fine and Gray models were performed. Predictive performances were compared by the area under the receiver operating characteristic (AUROC) differences after correction of optimistic by bootstrap samples. Best cutoffs to predict liver-related events were estimated by sensitivity and specificity maximization. RESULTS A total of 998 patients were included. Overall, 70.7% were men. Their median age was 46.8 years. According to LS value, 204 (20.4%) patients had cirrhosis. Overall, 39 patients experienced at least one liver-related event. In univariable analysis, LS AUROC curve was significantly superior to FIB-4 and APRI AUROC curves, being 87.9, 78.2, and 75.0%, respectively. After adjustment on age, CD4 levels, and insulin resistance, no differences were observed. The best cutoffs to identify patients at low or high risk of liver-related events were below 8.5, 1.00, and 0.35 and above 16.5, 4.00, and 1.75 for LS, FIB-4, and APRI, respectively. CONCLUSION To predict HCV-related events, APRI had lower performance than LS and FIB-4. FIB-4 is as good as LS to predict HCV-related events, suggesting that it can be used for the management of HIV/HCV co-infected patients and replace LS.
Collapse
|
18
|
Abstract
AIMS To assess associations of comorbidity patterns observed in people living with HIV (PLWH) with risk factors and health outcomes. METHODS Common patters of comorbidities in PLWH participating in the Pharmacokinetic and Clinical Observations in People Over Fifty study were determined using principal component analysis and a severity score for each pattern was derived. Associations between each pattern's severity score and risk factors were assessed using median regression. The independent associations of patterns' severity scores with self-reported physical and mental health (SF-36 summary scores) were assessed using linear regression, with functional impairment (Lawton IADL < 8) and hospitalization in last year using logistic regression and with number of general practitioner visits using Poisson regression. RESULTS A total of 1073 PLWH were analysed: 85.2% male, median (interquartile range) age 52 (47-59) years, 98% on therapy. Duration of HIV was associated with higher severity in 4/6 of patterns: cardiovascular diseases, mental health problems, metabolic disorders and chest/other infections (all P ≤ 0.001). Prior AIDS was associated with higher severity scores for the same patterns and for the pattern of cancers (P < 0.001). The pattern of cardiovascular diseases was associated with poorer physical health (P = 0.02), higher risk of functional impairment (P = 0.02) and hospitalization (P < 0.001) and with higher number of general practitioner visits (P < 0.001). Severity of mental health (all P < 0.001) and of chest/other infections patterns negatively affected all the five health outcomes. CONCLUSION Common patterns of comorbidities seen in PLWH appear to have different risk factors and to differently affect health outcomes. These findings may assist the development of targeted intervention to prevent, treat and manage the increasingly prevalent multimorbidity in PLWH.
Collapse
|
19
|
Brittain EL, Duncan MS, Chang J, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Goetz M, Akgun K, Crothers K, Zola C, Kim J, Gibert C, Pisani M, Morris A, Hsue P, Tindle HA, Justice A, Freiberg M. Increased Echocardiographic Pulmonary Pressure in HIV-infected and -uninfected Individuals in the Veterans Aging Cohort Study. Am J Respir Crit Care Med 2019; 197:923-932. [PMID: 29131651 DOI: 10.1164/rccm.201708-1555oc] [Citation(s) in RCA: 29] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
RATIONALE The epidemiology and prognostic impact of increased pulmonary pressure among HIV-infected individuals in the antiretroviral therapy era is not well described. OBJECTIVES To examine the prevalence, clinical features, and outcomes of increased echocardiographic pulmonary pressure in HIV-infected and -uninfected individuals. METHODS This study evaluated 8,296 veterans referred for echocardiography with reported pulmonary artery systolic pressure (PASP) estimates from the Veterans Aging Cohort study, an observational cohort of HIV-infected and -uninfected veterans matched by age, sex, race/ethnicity, and clinical site. The primary outcome was adjusted mortality by HIV status. MEASUREMENTS AND MAIN RESULTS PASP was reported in 2,831 HIV-infected and 5,465 HIV-uninfected veterans (follow-up [mean ± SD], 3.8 ± 2.6 yr). As compared with uninfected veterans, HIV-infected veterans with HIV viral load greater than 500 copies/ml (odds ratio, 1.27; 95% confidence interval [CI], 1.05-1.54) and those with CD4 cell count less than 200 cells/μl (odds ratio, 1.28; 95% CI, 1.02-1.60) had a higher prevalence of PASP greater than or equal to 40 mm Hg. As compared with uninfected veterans with a PASP less than 40 mm Hg, HIV-infected veterans with a PASP greater than or equal to 40 mm Hg had an increased risk of death (adjusted hazard ratio, 1.78; 95% CI, 1.57-2.01). This risk persisted even among participants without prevalent comorbidities (adjusted hazard ratio, 3.61; 95% CI, 2.17-6.01). The adjusted risk of mortality in HIV-infected veterans was higher at all PASP values than in uninfected veterans, including at values currently considered to be normal. CONCLUSIONS HIV-infected people with high HIV viral loads or low CD4 cell counts have a higher prevalence of increased PASP than uninfected people. Mortality risk in HIV-infected veterans increases at lower values of PASP than previously recognized and is present even among those without prevalent comorbidities. These findings may inform clinical decision-making regarding screening and surveillance of pulmonary hypertension in HIV-infected individuals.
Collapse
Affiliation(s)
- Evan L Brittain
- 1 Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.,2 Vanderbilt Translational and Clinical Cardiovascular Research Center, Nashville, Tennessee
| | - Meredith S Duncan
- 2 Vanderbilt Translational and Clinical Cardiovascular Research Center, Nashville, Tennessee
| | - Joyce Chang
- 3 Division of General Internal Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Olga V Patterson
- 4 Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.,5 Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
| | - Scott L DuVall
- 4 Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah.,5 Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah
| | - Cynthia A Brandt
- 6 Research Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven, Connecticut.,7 Department of Emergency Medicine and
| | - Kaku A So-Armah
- 8 Division of General Internal Medicine, Boston University, Boston, Massachusetts
| | - Matthew Goetz
- 9 Division of Infectious Diseases, Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, California
| | - Kathleen Akgun
- 10 Department of Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Kristina Crothers
- 11 Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, Washington
| | - Courtney Zola
- 12 Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Joon Kim
- 13 Division of Pulmonary and Critical Care Medicine, James J. Peters Veterans Affairs Medical Center, Bronx, New York
| | - Cynthia Gibert
- 14 Department of Medicine, George Washington University School of Medicine, Washington, D.C.,15 Division of Infectious Diseases, Washington D.C. Veterans Affairs Medical Center, Washington, D.C
| | - Margaret Pisani
- 16 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
| | - Alison Morris
- 16 Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
| | - Priscilla Hsue
- 17 Division of Cardiovascular Medicine, University of California San Francisco, San Francisco, California; and
| | - Hilary A Tindle
- 12 Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Amy Justice
- 6 Research Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven, Connecticut.,10 Department of Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Matthew Freiberg
- 1 Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.,2 Vanderbilt Translational and Clinical Cardiovascular Research Center, Nashville, Tennessee.,18 Veterans Health Administration-Tennessee Valley Healthcare System Geriatrics Research Education Clinical Center, Nashville, Tennessee
| |
Collapse
|
20
|
Freiberg MS, Chang CCH, Skanderson M, Patterson OV, DuVall SL, Brandt CA, So-Armah KA, Vasan RS, Oursler KA, Gottdiener J, Gottlieb S, Leaf D, Rodriguez-Barradas M, Tracy RP, Gibert CL, Rimland D, Bedimo RJ, Brown ST, Goetz MB, Warner A, Crothers K, Tindle HA, Alcorn C, Bachmann JM, Justice AC, Butt AA. Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study. JAMA Cardiol 2019; 2:536-546. [PMID: 28384660 DOI: 10.1001/jamacardio.2017.0264] [Citation(s) in RCA: 221] [Impact Index Per Article: 44.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Importance With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis. Objectives To investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk varies by sociodemographic and HIV-specific factors. Design, Setting, and Participants This study evaluated 98 015 participants without baseline cardiovascular disease from the Veterans Aging Cohort Study, an observational cohort of HIV-infected veterans and uninfected veterans matched by age, sex, race/ethnicity, and clinical site, enrolled on or after April 1, 2003, and followed up through September 30, 2012. The dates of the analysis were October 2015 to November 2016. Exposure Human immunodeficiency virus infection. Main Outcomes and Measures Outcomes included HFpEF (EF≥50%), borderline HFpEF (EF 40%-49%), HFrEF (EF<40%), and HF of unknown type (EF missing). Results Among 98 015 participants, the mean (SD) age at enrollment in the study was 48.3 (9.8) years, 97.0% were male, and 32.2% had HIV infection. During a median follow-up of 7.1 years, there were 2636 total HF events (34.6% were HFpEF, 15.5% were borderline HFpEF, 37.1% were HFrEF, and 12.8% were HF of unknown type). Compared with uninfected veterans, HIV-infected veterans had an increased risk of HFpEF (hazard ratio [HR], 1.21; 95% CI, 1.03-1.41), borderline HFpEF (HR, 1.37; 95% CI, 1.09-1.72), and HFrEF (HR, 1.61; 95% CI, 1.40-1.86). The risk of HFrEF was pronounced in veterans younger than 40 years at baseline (HR, 3.59; 95% CI, 1.95-6.58). Among HIV-infected veterans, time-updated HIV-1 RNA viral load of at least 500 copies/mL compared with less than 500 copies/mL was associated with an increased risk of HFrEF, and time-updated CD4 cell count less than 200 cells/mm3 compared with at least 500 cells/mm3 was associated with an increased risk of HFrEF and HFpEF. Conclusions and Relevance Individuals who are infected with HIV have an increased risk of HFpEF, borderline HFpEF, and HFrEF compared with uninfected individuals. The increased risk of HFrEF can manifest decades earlier than would be expected in a typical uninfected population. Future research should focus on prevention, risk stratification, and identification of the mechanisms for HFrEF and HFpEF in the HIV-infected population.
Collapse
Affiliation(s)
- Matthew S Freiberg
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee2Geriatric Research Education and Clinical Centers, Veterans Affairs Tennessee Valley Healthcare System, Nashville
| | - Chung-Chou H Chang
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Melissa Skanderson
- Research Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven
| | - Olga V Patterson
- Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City6Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City
| | - Scott L DuVall
- Department of Veterans Affairs Salt Lake City Health Care System, Salt Lake City6Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City
| | - Cynthia A Brandt
- Research Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven7Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut
| | - Kaku A So-Armah
- Division of General Internal Medicine, Boston University, Boston, Massachusetts
| | - Ramachandran S Vasan
- Department of Medicine, Boston University School of Medicine, Boston, Massachusetts
| | - Kris Ann Oursler
- Department of Medicine, University of Maryland School of Medicine, Baltimore11Division of Infectious Diseases, Baltimore Veterans Affairs Health Care System, Baltimore, Maryland12Division of Cardiology, Baltimore Veterans Affairs Health Care System, Baltimore, Maryland
| | - John Gottdiener
- Department of Medicine, University of Maryland School of Medicine, Baltimore
| | - Stephen Gottlieb
- Department of Medicine, University of Maryland School of Medicine, Baltimore
| | - David Leaf
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles
| | - Maria Rodriguez-Barradas
- Department of Medicine, Baylor College of Medicine, Houston, Texas15Division of Infectious Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas
| | - Russell P Tracy
- Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington
| | - Cynthia L Gibert
- Department of Medicine, George Washington University School of Medicine, Washington, DC18Division of Infectious Diseases, Washington DC Veterans Affairs Medical Center, Washington, DC
| | - David Rimland
- Department of Medicine, Emory University School of Medicine, Atlanta, Georgia20Division of Infectious Diseases, Atlanta Veterans Affairs Medical Center, Atlanta, Georgia
| | - Roger J Bedimo
- Department of Medicine, Veterans Affairs North Texas Health Care System, Dallas
| | - Sheldon T Brown
- Division of Infectious Diseases, James J. Peters Veterans Affairs Medical Center, Bronx, New York23Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York
| | - Matthew Bidwell Goetz
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles24Division of Infectious Diseases, Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California
| | - Alberta Warner
- Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles25Division of Cardiology, Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California
| | - Kristina Crothers
- Department of Medicine, University of Washington School of Medicine, Seattle
| | - Hilary A Tindle
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Charles Alcorn
- Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania
| | - Justin M Bachmann
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Amy C Justice
- Research Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven29Department of Medicine, Yale School of Medicine, New Haven, Connecticut
| | - Adeel A Butt
- Department of Medicine, Weill Cornell Medical College, New York, New York
| |
Collapse
|
21
|
Kim HN, Nance RM, Williams-Nguyen JS, Chris Delaney JA, Crane HM, Cachay ER, Martin J, Mathews WC, Chander G, Franco R, Hurt CB, Geng EH, Rodriguez B, Moore RD, Saag MS, Kitahata MM. Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. Open Forum Infect Dis 2019; 6:ofz100. [PMID: 30949539 PMCID: PMC6441587 DOI: 10.1093/ofid/ofz100] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2018] [Accepted: 02/25/2019] [Indexed: 02/06/2023] Open
Abstract
Background Direct-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions. Methods The primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or <25 IU/mL ≥10 weeks after treatment. We calculated SVR rates and 95% confidence intervals (CIs) in a modified intent-to-treat analysis. We repeated this analysis after multiply imputing missing SVR values. Results Among 642 DAA-treated patients, 536 had SVR assessments. The median age was 55 years; 79% were men, 59% black, and 32% white. Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%-97.9%). Patients who were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower SVR rate was early discontinuation (77.8%; 95% CI, 52.4%-93.6%). Similar results were seen in multiply imputed data sets. Conclusions Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.
Collapse
Affiliation(s)
- H Nina Kim
- Department of Medicine, University of Washington, Seattle
| | - Robin M Nance
- Department of Medicine, University of Washington, Seattle
| | | | | | - Heidi M Crane
- Department of Medicine, University of Washington, Seattle
| | | | - Jeffrey Martin
- Department of Medicine, University of California, San Francisco
| | | | | | - Ricardo Franco
- Department of Medicine, University of Alabama, Birmingham
| | - Christopher B Hurt
- Institute for Global Health & Infectious Diseases, University of North Carolina, Chapel Hill
| | - Elvin H Geng
- Department of Medicine, University of California, San Francisco
| | | | - Richard D Moore
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Michael S Saag
- Department of Medicine, University of Alabama, Birmingham
| | | | | |
Collapse
|
22
|
Alcohol and Mortality: Combining Self-Reported (AUDIT-C) and Biomarker Detected (PEth) Alcohol Measures Among HIV Infected and Uninfected. J Acquir Immune Defic Syndr 2018; 77:135-143. [PMID: 29112041 DOI: 10.1097/qai.0000000000001588] [Citation(s) in RCA: 33] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
BACKGROUND Unhealthy alcohol use may be particularly detrimental among individuals living with HIV and/or hepatitis C virus (HCV), and is often under-reported. Direct biomarkers of alcohol exposure may facilitate improved detection of alcohol use. METHODS We evaluated the association of alcohol exposure determined by both self-report [Alcohol Use Disorders Identification Test-Consumption (AUDIT-C)] and a direct biomarker [phosphatidylethanol (PEth)], with mortality among HIV-infected and HIV-uninfected in the Veterans Aging Cohort Study-Biomarker Cohort. We considered PEth <8 ng/mL to represent no alcohol use. Alcohol exposure by AUDIT-C scores [0, 1-3/1-2 (men/women), 4-7/3-7 (men/women), 8-12] and PEth (<8, ≥8) was combined into categories to model the relationship of alcohol with mortality. Participants were followed from blood collection date for 5 years or until death within 5 years. RESULTS The sample included 2344 (1513 HIV+; 831 uninfected) individuals, 95% men. During a median follow-up of 5 years, 13% died. Overall, 36% were infected with HCV (40% HIV+/HCV+, 27% HIV-/HCV+). Overall, 43% (1015/2344) had AUDIT-C = 0 (abstinence). Of these, 15% (149/1015) had PEth ≥8 suggesting recent alcohol exposure. Among those with AUDIT-C = 0, HCV+ individuals were more likely to have PEth ≥8. After controlling for age, sex, race, HIV, HCV, and HIV viral suppression, those with AUDIT-C = 0 but PEth ≥8 had the highest risk of mortality (adjusted hazard ratio 2.15, 95% confidence interval: 1.40 to 3.29). CONCLUSIONS PEth in addition to self-report may improve detection of alcohol use in clinical settings, particularly among those at increased risk of harm from alcohol use. Individuals infected with HCV were more likely to under-report alcohol use.
Collapse
|
23
|
Hawkins KL, Gordon KS, Levin MJ, Weinberg A, Battaglia C, Rodriguez-Barradas MC, Brown ST, Rimland D, Justice A, Tate J, Erlandson KM. Herpes Zoster and Herpes Zoster Vaccine Rates Among Adults Living With and Without HIV in the Veterans Aging Cohort Study. J Acquir Immune Defic Syndr 2018; 79:527-533. [PMID: 30179984 PMCID: PMC6203599 DOI: 10.1097/qai.0000000000001846] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Despite historically high rates of herpes zoster among people living with HIV (PLWH), comparative studies of herpes zoster by HIV serostatus are lacking since the advent of combination antiretroviral therapy and availability of zoster vaccine. METHODS Annual rates (2002-2015) of first-episode herpes zoster and zoster vaccination were calculated for PLWH and uninfected adults in the Veterans Aging Cohort Study and stratified by HIV serostatus and age. Herpes zoster was captured using ICD9 codes and vaccine receipt with procedural codes and pharmacy data. RESULTS Of 45,177 PLWH and 103,040 uninfected veterans, rates of herpes zoster decreased among PLWH (17.6-8.1/1000) over the study period but remained higher than uninfected adults (4.1/1000) at the end of study period. Rates were higher in PLWH with lower CD4 (<200 vs >500 cells/µL: 18.0 vs 6.8/1000) and unsuppressed vs suppressed HIV-1 RNA (21.8 vs 7.1/1000). Restricted to virologically suppressed participants with CD4 >350 cells per microliter, herpes zoster rates were similar among PLWH aged younger than 60 years and aged 60 years and older in 2015 (6.6 vs 6.7/1000) but higher than all uninfected age groups. At study end, cumulative receipt of zoster vaccine for PLWH aged 60 years and older was less than half that of uninfected veterans: 98.7 vs 215.2/1000. CONCLUSIONS Herpes zoster rates among PLWH have markedly decreased, but, even in cART-treated individuals, remain 50% higher than uninfected adults. Lower rates of zoster vaccine receipt combined with high rates of herpes zoster support the need for a safe and effective vaccine against herpes zoster for PLWH, formal zoster vaccine guidelines for PLWH, and consideration for expanded use at younger ages.
Collapse
Affiliation(s)
- Kellie L Hawkins
- Denver Public Health, Denver, CO
- Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado, Aurora, CO
| | - Kirsha S Gordon
- Veterans Affairs Connecticut Healthcare System, West Haven, CT
- Yale University Schools of Medicine and Public Health, New Haven, CT
| | - Myron J Levin
- Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado, Aurora, CO
| | - Adriana Weinberg
- Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado, Aurora, CO
| | - Catherine Battaglia
- Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado, Aurora, CO
| | - Maria C Rodriguez-Barradas
- Department of Medicine, Infectious Diseases Section, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, TX
| | - Sheldon T Brown
- Department of Medicine, James J. Peters Veterans Affairs Medical Center, Mount Sinai School of Medicine, New York, NY
| | - David Rimland
- Division of Infectious Diseases, Atlanta Veterans Affairs Medical Center, Emory University School of Medicine, Atlanta, GA
| | - Amy Justice
- Veterans Affairs Connecticut Healthcare System, West Haven, CT
- Yale University Schools of Medicine and Public Health, New Haven, CT
| | - Janet Tate
- Veterans Affairs Connecticut Healthcare System, West Haven, CT
- Yale University Schools of Medicine and Public Health, New Haven, CT
| | - Kristine M Erlandson
- Division of Infectious Diseases, Anschutz Medical Campus, University of Colorado, Aurora, CO
| |
Collapse
|
24
|
De Francesco D, Verboeket SO, Underwood J, Bagkeris E, Wit FW, Mallon PWG, Winston A, Reiss P, Sabin CA. Patterns of Co-occurring Comorbidities in People Living With HIV. Open Forum Infect Dis 2018; 5:ofy272. [PMID: 30465014 PMCID: PMC6239080 DOI: 10.1093/ofid/ofy272] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Accepted: 10/19/2018] [Indexed: 12/11/2022] Open
Abstract
Background The aims of this study were to identify common patterns of comorbidities observed in people living with HIV (PLWH), using a data-driven approach, and evaluate associations between patterns identified. Methods A wide range of comorbidities were assessed in PLWH participating in 2 independent cohorts (POPPY: UK/Ireland; AGEhIV: Netherlands). The presence/absence of each comorbidity was determined using a mix of self-reported medical history, concomitant medications, health care resource use, and laboratory parameters. Principal component analysis (PCA) based on Somers' D statistic was applied to identify patterns of comorbidities. Results PCA identified 6 patterns among the 1073 POPPY PLWH (85.2% male; median age [interquartile range {IQR}], 52 [47-59] years): cardiovascular diseases (CVDs), sexually transmitted diseases (STDs), mental health problems, cancers, metabolic disorders, chest/other infections. The CVDs pattern was positively associated with cancer (r = .32), metabolic disorder (r = .38), mental health (r = .16), and chest/other infection (r = .17) patterns (all P < .001). The mental health pattern was correlated with all the other patterns (in particular cancers: r = .20; chest/other infections: r = .27; both P < .001). In the 598 AGEhIV PLWH (87.6% male; median age [IQR], 53 [48-59] years), 6 patterns were identified: CVDs, chest/liver, HIV/AIDS events, mental health/neurological problems, STDs, and general health. The general health pattern was correlated with all the other patterns (in particular CVDs: r = .14; chest/liver: r = .15; HIV/AIDS events: r = .31; all P < .001), except STDs (r = -.02; P = .64). Conclusions Comorbidities in PLWH tend to occur in nonrandom patterns, reflecting known pathological mechanisms and shared risk factors, but also suggesting potential previously unknown mechanisms. Their identification may assist in adequately addressing the pathophysiology of increasingly prevalent multimorbidity in PLWH.
Collapse
Affiliation(s)
| | - Sebastiaan O Verboeket
- Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands
| | | | | | - Ferdinand W Wit
- Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands
| | | | - Alan Winston
- Division of Infectious Diseases, Imperial College London, London, UK
| | - Peter Reiss
- Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam and Amsterdam Institute for Global Health and Development, Amsterdam, the Netherlands
| | - Caroline A Sabin
- Institute for Global Health, University College London, London, UK
| |
Collapse
|
25
|
So-Armah KA, Lim JK, Re VL, Tate JP, Chang CCH, Butt AA, Gibert CL, Rimland D, Marconi VC, Goetz MB, Rodriguez-Barradas MC, Budoff MJ, Tindle HA, Samet JH, Justice AC, Freiberg MS. FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients. Hepatology 2017; 66:1286-1295. [PMID: 28543215 PMCID: PMC5609079 DOI: 10.1002/hep.29285] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Revised: 05/10/2017] [Accepted: 05/19/2017] [Indexed: 12/13/2022]
Abstract
UNLABELLED Liver fibrosis is common, particularly in individuals who are infected with human immunodeficiency virus (HIV). HIV-infected individuals have excess congestive heart failure (CHF) risk compared with uninfected people. It remains unknown whether liver fibrosis stage influences the CHF risk or if HIV or hepatitis C virus (HCV) infection modifies this association. Our objectives were to assess whether 1) stage of liver fibrosis is independently associated with incident CHF and 2) the association between stage of liver fibrosis and incident CHF is modified by HIV/HCV status. Participants alive on or after April 1, 2003, in the Veterans Aging Cohort Study were included. Those without prevalent cardiovascular disease were followed until their first CHF event, death, last follow-up date, or December 31, 2011. Liver fibrosis was measured using the fibrosis 4 index (FIB-4), which is calculated using age, aminotransferases, and platelets. Cox proportional hazards regression models were adjusted for cardiovascular disease risk factors. Among 96,373 participants over 6.9 years, 3844 incident CHF events occurred. FIB-4 between 1.45 and 3.25 (moderate fibrosis) and FIB-4 > 3.25 (advanced fibrosis/cirrhosis) were associated with CHF (hazard ratio [95% confidence interval], 1.17 [1.07-1.27] and 1.65 [1.43-1.92], respectively). The association of advanced fibrosis/cirrhosis and incident CHF persisted regardless of HIV/HCV status. CONCLUSION Moderate and advanced liver fibrosis/cirrhosis are associated with an increased risk of CHF. The association for advanced fibrosis/cirrhosis persists even among participants without hepatitis C and/or HIV infection. Assessing liver health may be important for reducing the risk of future CHF events, particularly among HIV and hepatitis C infected people among whom cardiovascular disease risk is elevated and liver disease is common. (Hepatology 2017;66:1286-1295).
Collapse
Affiliation(s)
| | - Joseph K. Lim
- Yale University School of Medicine, New Haven, CT, USA
| | - Vincent Lo Re
- Philadelphia VA Medical Center; University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - Janet P. Tate
- VA Connecticut Healthcare System, West Haven, CT,Yale University School of Medicine, New Haven, CT, USA
| | - Chung-Chou H. Chang
- University of Pittsburgh Schools of Medicine and Public Health, Pittsburgh, PA, USA
| | - Adeel A. Butt
- Weill Cornell Medical College, NY, USA,VA Pittsburgh Healthcare System, PA, USA,Hamad Healthcare Quality Institute, Hamad Medical Corporation, Doha, Qatar
| | - Cynthia L. Gibert
- VA Medical Center & George Washington University School of Medicine and Public Health, Washington, DC, USA
| | - David Rimland
- Atlanta VA Medical Center & Emory University School of Medicine, Atlanta, GA
| | - Vincent C. Marconi
- Atlanta VA Medical Center; Emory University School of Medicine and Rollins School of Public Health, Atlanta, GA
| | - Matthew B. Goetz
- VA Greater Los Angeles Healthcare System and the David Geffen School of Medicine at the University of California, Los Angeles, CA 90073, USA
| | | | - Matthew J. Budoff
- Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Los Angeles, CA, USA
| | | | - Jeffrey H. Samet
- Boston University Schools of Medicine and Public Health, Boston Medical Center, Boston, MA, USA
| | - Amy C. Justice
- VA Connecticut Healthcare System, West Haven, CT,Yale University Schools of Medicine and Public Health, New Haven, CT, USA
| | - Matthew S. Freiberg
- Vanderbilt University School of Medicine; Nashville Veterans Affairs Medical Center, Tennessee Valley Healthcare System, Nashville, TN, USA
| | | |
Collapse
|
26
|
Butt ZA, Shrestha N, Wong S, Kuo M, Gesink D, Gilbert M, Wong J, Yu A, Alvarez M, Samji H, Buxton JA, Johnston JC, Cook VJ, Roth D, Consolacion T, Murti M, Hottes TS, Ogilvie G, Balshaw R, Tyndall MW, Krajden M, Janjua NZ. A syndemic approach to assess the effect of substance use and social disparities on the evolution of HIV/HCV infections in British Columbia. PLoS One 2017; 12:e0183609. [PMID: 28829824 PMCID: PMC5568727 DOI: 10.1371/journal.pone.0183609] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/05/2017] [Accepted: 08/08/2017] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Co-occurrence of social conditions and infections may affect HIV/HCV disease risk and progression. We examined the changes in relationship of these social conditions and infections on HIV and hepatitis C virus (HCV) infections over time in British Columbia during 1990-2013. METHODS The BC Hepatitis Testers Cohort (BC-HTC) includes ~1.5 million individuals tested for HIV or HCV, or reported as a case of HCV, HIV, HBV, or tuberculosis linked to administrative healthcare databases. We classified HCV and HIV infection status into five combinations: HIV-/HCV-, HIV+monoinfected, HIV-/HCV+seroconverters, HIV-/HCV+prevalent, and HIV+/HCV+. RESULTS Of 1.37 million eligible individuals, 4.1% were HIV-/HCV+prevalent, 0.5% HIV+monoinfected, 0.3% HIV+/HCV+ co-infected and 0.5% HIV-/HCV+seroconverters. Overall, HIV+monoinfected individuals lived in urban areas (92%), had low injection drug use (IDU) (4%), problematic alcohol use (4%) and were materially more privileged than other groups. HIV+/HCV+ co-infected and HIV-/HCV+seroconverters were materially most deprived (37%, 32%), had higher IDU (28%, 49%), problematic alcohol use (14%, 17%) and major mental illnesses (12%, 21%). IDU, opioid substitution therapy, and material deprivation increased in HIV-/HCV+seroconverters over time. In multivariable multinomial regression models, over time, the odds of IDU declined among HIV-/HCV+prevalent and HIV+monoinfected individuals but not in HIV-/HCV+seroconverters. Declines in odds of problematic alcohol use were observed in HIV-/HCV+seroconverters and coinfected individuals over time. CONCLUSIONS These results highlight need for designing prevention, care and support services for HIV and HCV infected populations based on the evolving syndemics of infections and social conditions which vary across groups.
Collapse
Affiliation(s)
- Zahid Ahmad Butt
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Nabin Shrestha
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
| | - Stanley Wong
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Margot Kuo
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Dionne Gesink
- Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
| | - Mark Gilbert
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Jason Wong
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Amanda Yu
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Maria Alvarez
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Hasina Samji
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Jane A. Buxton
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - James C. Johnston
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Victoria J. Cook
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - David Roth
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Theodora Consolacion
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Michelle Murti
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- Fraser Health, Surrey, British Columbia, Canada
| | - Travis S. Hottes
- BCCDC Public Health Laboratory, Vancouver, British Columbia, Canada
| | - Gina Ogilvie
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Robert Balshaw
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Mark W. Tyndall
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | - Mel Krajden
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
- BCCDC Public Health Laboratory, Vancouver, British Columbia, Canada
| | - Naveed Z. Janjua
- School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada
- British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada
| | | |
Collapse
|
27
|
Chen R, Scherzer R, Hsue PY, Jotwani V, Estrella MM, Horberg MA, Grunfeld C, Shlipak MG. Association of Tenofovir Use With Risk of Incident Heart Failure in HIV-Infected Patients. J Am Heart Assoc 2017; 6:e005387. [PMID: 28438737 PMCID: PMC5533031 DOI: 10.1161/jaha.116.005387] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/24/2016] [Accepted: 02/21/2017] [Indexed: 01/12/2023]
Abstract
BACKGROUND The antiretroviral medication, tenofovir disoproxil fumarate (TDF), is used by most human immunodeficiency virus-infected persons in the United States despite higher risks of chronic kidney disease. Although chronic kidney disease is a strong risk factor for heart failure (HF), the association of TDF with incident HF is unclear. METHODS AND RESULTS We identified 21 435 human immunodeficiency virus-infected patients in the United States Veterans Health Administration actively using antiretrovirals between 2002 and 2011. We excluded patients with a prior diagnosis of HF. TDF was analyzed categorically (current, past, or never use) and continuously (per year of use). Proportional hazards regression and fully adjusted marginal structural models were used to determine the association of TDF exposure with risk of incident HF after adjustment for demographic, human immunodeficiency virus-related, and cardiovascular risk factors. During follow-up, 438 incident HF events occurred. Unadjusted 5-year event rates for current, past, and never users of TDF were 0.9 (95%CI 0.7-1.1), 1.7 (1.4-2.2), and 4.5 (3.9-5.0), respectively. In fully adjusted analyses, HF risk was markedly lower in current TDF users (HR=0.68; 95%CI 0.53-0.86) compared with never users. Among current TDF users, each additional year of TDF exposure was associated with a 21% lower risk of incident HF (95%CI: 0.68-0.92). When limited to antiretroviral-naive patients, HF risk remained lower in current TDF users (HR=0.53; 95%CI 0.36-0.78) compared to never users. CONCLUSIONS Among a large national cohort of human immunodeficiency virus-infected patients, TDF use was strongly associated with lower risk of incident HF. These findings warrant confirmation in other populations, both with TDF and the recently approved tenofovir alafenamide fumarate.
Collapse
Affiliation(s)
- Ruijun Chen
- Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, CA
| | - Rebecca Scherzer
- Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, CA
- Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA
| | - Priscilla Y Hsue
- Division of Cardiology, San Francisco General Hospital, San Francisco, CA
| | - Vasantha Jotwani
- Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, CA
- Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA
| | - Michelle M Estrella
- Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, CA
- Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA
| | | | - Carl Grunfeld
- Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, CA
- Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA
| | - Michael G Shlipak
- Department of Medicine, San Francisco VA Medical Center and University of California, San Francisco, CA
- Kidney Health Research Collaborative, University of California San Francisco, San Francisco, CA
| |
Collapse
|
28
|
Cox J, Hamelin AM, McLinden T, Moodie EEM, Anema A, Rollet-Kurhajec KC, Paradis G, Rourke SB, Walmsley SL, Klein MB. Food Insecurity in HIV-Hepatitis C Virus Co-infected Individuals in Canada: The Importance of Co-morbidities. AIDS Behav 2017; 21:792-802. [PMID: 26912217 PMCID: PMC5306219 DOI: 10.1007/s10461-016-1326-9] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
While research has begun addressing food insecurity (FI) in HIV-positive populations, knowledge regarding FI among individuals living with HIV-hepatitis C virus (HCV) co-infection is limited. This exploratory study examines sociodemographic, socioeconomic, behavioral, and clinical factors associated with FI in a cohort of HIV-HCV co-infected individuals in Canada. We analyzed longitudinal data from the Food Security and HIV-HCV Co-infection Study of the Canadian Co-infection Cohort collected between November 2012-June 2014 at 15 health centres. FI was measured using the Household Food Security Survey Module and classified using Health Canada criteria. Generalized estimating equations were used to assess factors associated with FI. Among 525 participants, 59 % experienced FI at their first study visit (baseline). Protective factors associated with FI (p < 0.05) included: enrolment at a Quebec study site (aOR: 0.42, 95 % CI: 0.27, 0.67), employment (aOR: 0.55, 95 % CI: 0.35, 0.87), and average personal monthly income (aOR per $100 CAD increase: 0.98, 95 % CI: 0.97, 0.99). Risk factors for FI included: recent injection drug use (aOR: 1.98, 95 % CI: 1.33, 2.96), trading away food (aOR: 5.23, 95 % CI: 2.53, 10.81), and recent experiences of depressive symptoms (aOR: 2.11, 95 % CI: 1.48, 3.01). FI is common in this co-infected population. Engagement of co-infected individuals in substance use treatments, harm reduction programs, and mental health services may mitigate FI in this vulnerable subset of the HIV-positive population.
Collapse
Affiliation(s)
- Joseph Cox
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada.
- Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada.
- CIHR Canadian HIV Trials Network, Vancouver, BC, Canada.
| | - Anne-Marie Hamelin
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada
| | - Taylor McLinden
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada
| | - Erica E M Moodie
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada
| | - Aranka Anema
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA
- Department of Medicine, Boston Children's Hospital, Boston, MA, USA
| | | | - Gilles Paradis
- Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Purvis Hall, 1020 Pine Avenue West, Montreal, QC, H3A 1A2, Canada
| | - Sean B Rourke
- Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada
- The Ontario HIV Treatment Network, Toronto, ON, Canada
- Department of Psychiatry, University of Toronto, Toronto, ON, Canada
| | - Sharon L Walmsley
- Department of Medicine, University of Toronto, Toronto, ON, Canada
- Division of Infectious Diseases, University Health Network, Toronto, ON, Canada
| | - Marina B Klein
- Chronic Viral Illness Service, McGill University Health Centre, Montreal, QC, Canada
| |
Collapse
|
29
|
Fialho R, Pereira M, Rusted J, Whale R. Depression in HIV and HCV co-infected patients: a systematic review and meta-analysis. PSYCHOL HEALTH MED 2017; 22:1089-1104. [PMID: 28100073 DOI: 10.1080/13548506.2017.1280177] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The aim of this study was to carry out a systematic review and meta-analysis of the differences in the prevalence of depression and presence of depressive symptoms between HIV/HCV co-infection, HIV mono-infection, and hepatitis C virus (HCV) mono-infection. A systematic electronic search of bibliographic databases was performed to locate articles published from the earliest available online until December 2014. Outcomes of depression were based on clinical interviews and validated self-reported measures of depression/depressive symptoms. Of the 188 records initially screened, 29 articles were included in the descriptive systematic review and six were included in the meta-analysis. The meta-analytic results indicated that, as measured by self-reported measures of depression, HIV/HCV co-infected patients were significantly more likely to report depressive symptoms than either HIV (SMD = .24, 95% CI: .03-.46, p = .02) or HCV mono-infected (SMD = .55, 95% CI: .17-.94, p = .005) patients. The variability of the results of the reviewed studies, largely dependent on the samples' characteristics and the methods of assessment of depression, suggests that a clear interpretation of how depression outcomes are affected by the presence of HIV/HCV co-infection is still needed. Failing to diagnose depression or to early screen depressive symptoms may have a significant impact on patients' overall functioning and compromise treatments' outcomes.
Collapse
Affiliation(s)
- Renata Fialho
- a School of Psychology , University of Sussex , Brighton , UK.,b Sussex Partnership NHS Foundation Trust , Brighton , UK
| | - Marco Pereira
- c Faculty of Psychology and Educational Sciences , University of Coimbra , Coimbra , Portugal
| | - Jennifer Rusted
- a School of Psychology , University of Sussex , Brighton , UK
| | - Richard Whale
- b Sussex Partnership NHS Foundation Trust , Brighton , UK.,d Brighton and Sussex Medical School , Brighton , UK
| |
Collapse
|
30
|
Katsounas A, Wilting KR, Lempicki RA, Schlaak JF, Gerken G. Microarrays-Enabled Hypothesis Generation: The Suspect Role of FNBP-1 in Neuropsychiatric Pathogenesis Associated with HIV and/or HCV Infection. JOURNAL OF AIDS & CLINICAL RESEARCH 2016; 7:641. [PMID: 28255515 PMCID: PMC5330367 DOI: 10.4172/2155-6113.1000641] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The spectrum of neuropsychiatric illness (NI) associated with the Human Immunodeficiency Virus (HIV) and/or the Hepatitis C Virus (HCV) is far reaching and significantly impacts the clinical presentation and outcome of infected persons; however, the etiological and pathophysiological background remains partially understood. The present work was aimed to investigate the potential significance of formin binding protein 1 (FNBP-1)-dependent pathways in NI-pathogenesis by elaborating on previous microarray-based research in HIV and/or HCV-infected patients receiving interferon-α (IFN-α) immunotherapy via a rigorous data mining procedure. METHODS Using microarray data of peripheral whole blood (PB) samples obtained from HCV mono-infected persons (n=25, Affymetrix® HG-U133A_2) 12 h before and after the 1st dose of pegylated IFN-α (PegIFN-α), we re-applied the same analytical algorithm that we had developed and published in an earlier study with HIV/HCV co-infected subjects (N=28, Affymetrix® HG-U133A), in order to evaluate reproducibility of potential NI-related molecular findings in an independent cohort. RESULTS Among 28 gene expression profiles (HIV/HCV: N=9 vs. HCV: N=19) selected by applying different thresholds (a Mean Fold Difference value (MFD) in gene expression of ≥ 0.38 (log2) and/or P value from <0.05 to ≤ 0.1) FNBP-1 was identified as the only overlapping marker, which also exhibited a consistent upregulation in association with the development of NI in both cohorts. Previous functional annotation analysis had classified FNBP-1 as molecule with significant enrichment in various brain tissues (P<0.01). CONCLUSION Our current findings are strongly arguing for intensifying research into the FNBP-1-related mechanisms that may be conferring risk for or resistance to HIV- and/or HCV-related NI.
Collapse
Affiliation(s)
- A Katsounas
- Department of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
- Laboratory of Immunopathogenesis and Bioinformatics, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA
| | - KR Wilting
- Department for Medical Microbiology and Infection Prevention, University Medical Center Groningen, Hanzeplein 1 (9713 GZ) Groningen, the Netherlands
| | - RA Lempicki
- Laboratory of Immunopathogenesis and Bioinformatics, Leidos Biomedical Research, Inc., National Cancer Institute at Frederick, Frederick, MD 21702, USA
| | - JF Schlaak
- Evangelisches Klinikum Niederrhein gGmbH, Duisburg, Germany
| | - G Gerken
- Department of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
| |
Collapse
|
31
|
Khambaty T, Stewart JC, Gupta SK, Chang CCH, Bedimo RJ, Budoff MJ, Butt AA, Crane H, Gibert CL, Leaf DA, Rimland D, Tindle HA, So-Armah KA, Justice AC, Freiberg MS. Association Between Depressive Disorders and Incident Acute Myocardial Infarction in Human Immunodeficiency Virus-Infected Adults: Veterans Aging Cohort Study. JAMA Cardiol 2016; 1:929-937. [PMID: 27557332 PMCID: PMC5621480 DOI: 10.1001/jamacardio.2016.2716] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
Importance With the advent of highly effective antiretroviral therapy and improved survival, human immunodeficiency virus (HIV)-infected people are living longer and are now at an increased risk for cardiovascular disease (CVD). There is an urgent need to identify novel risk factors and primary prevention approaches for CVD in HIV. Although depression is prevalent in HIV-infected adults and is associated with future CVD in the general population, its association with CVD events has not been examined in the HIV-infected population. Objective To examine whether depressive disorders are prospectively associated with incident acute myocardial infarction (AMI) in a large cohort of adults with HIV. Design, Setting, and Participants Included in this cohort study were 26 144 HIV-infected veterans without CVD at baseline (1998-2003) participating in the US Department of Veterans Affairs Veterans Aging Cohort Study from April 1, 2003, through December 31, 2009. At baseline, 4853 veterans (19%) with major depressive disorder (MDD; International Classification of Diseases, Ninth Revision [ICD-9] codes 296.2 and 296.3) and 2296 (9%) with dysthymic disorder (ICD-9 code 300.4) were identified. The current analysis was conducted from January 2015 to November 2015. Main Outcomes and Measures Incident AMI (defined by discharge summary documentation, enzyme/electrocardiography evidence of AMI, inpatient ICD-9 code for AMI (410), or AMI as underlying cause of death [International Statistical Classification of Diseases and Related Health Problems, Tenth Revision code 121]) between the enrollment date and December 31, 2009. Results The mean (SD) age of those with MDD was 47.3 (7.9) years and for those without MDD was 48.2 (9.7) years. During 5.8 years of follow-up, 490 AMI events (1.9%) occurred. Baseline MDD was associated with incident AMI after adjusting for demographics (hazard ratio [HR], 1.31; 95% CI, 1.05-1.62), CVD risk factors (HR, 1.29; 95% CI, 1.04-1.60), and HIV-specific factors (HR, 1.30; 95% CI, 1.05-1.62). Further adjustment for hepatitis C, renal disease, substance abuse, and hemoglobin level (HR, 1.25; 95% CI, 1.00-1.56) and antidepressant use (HR, 1.12; 95% CI, 0.87-1.42) attenuated associations. Baseline dysthymic disorder was not associated with incident AMI. Conclusions and Relevance We report novel evidence that HIV-infected adults with MDD have a 30% increased risk for AMI than HIV-infected adults without MDD after adjustment for many potential confounders. Our findings raise the possibility that MDD may be independently associated with incident atherosclerotic CVD in the HIV-infected population.
Collapse
Affiliation(s)
- Tasneem Khambaty
- Department of Psychology, University of Miami, Coral Gables, Florida
| | - Jesse C Stewart
- Department of Psychology, Indiana University-Purdue University Indianapolis, Indianapolis
| | - Samir K Gupta
- Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis
| | - Chung-Chou H Chang
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
| | - Roger J Bedimo
- Department of Medicine, VA North Texas Health Care System, Dallas
| | | | - Adeel A Butt
- VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania8Weill Cornell Medical College, Doha, Qatar, and New York, New York9Hamad Healthcare Quality Institute and Hamad Medical Corp, Doha, Qatar
| | - Heidi Crane
- University of Washington School of Medicine, Seattle
| | | | - David A Leaf
- University of California, Los Angeles School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, Los Angeles
| | - David Rimland
- Division of Infectious Diseases, Emory University School of Medicine, Atlanta, Georgia
| | - Hilary A Tindle
- Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee
| | - Kaku A So-Armah
- Division of General Internal Medicine, Boston University, Boston, Massachusetts
| | - Amy C Justice
- Department of Medicine, Yale University School of Medicine, and VA Connecticut Healthcare System, West Haven Affiliation, New Haven
| | - Matthew S Freiberg
- Cardiovascular Medicine Division, Vanderbilt University School of Medicine, Nashville, Tennessee18Tennessee Valley Geriatric Research Education and Clinical Center, Nashville
| |
Collapse
|
32
|
Shuper PA, Joharchi N, Irving H, Fletcher D, Kovacs C, Loutfy M, Walmsley SL, Wong DKH, Rehm J. Differential predictors of ART adherence among HIV-monoinfected versus HIV/HCV-coinfected individuals. AIDS Care 2016; 28:954-62. [PMID: 26971360 DOI: 10.1080/09540121.2016.1158396] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Although adherence is an important key to the efficacy of antiretroviral therapy (ART), many people living with HIV (PLWH) fail to maintain optimal levels of ART adherence over time. PLWH with the added burden of Hepatitis C virus (HCV) coinfection possess unique challenges that potentially impact their motivation and ability to adhere to ART. The present investigation sought to (1) compare ART adherence levels among a sample of HIV/HCV-coinfected versus HIV-monoinfected patients, and (2) identify whether ART-related clinical and psychosocial correlates differ by HCV status. PLWH receiving ART (N = 215: 105 HIV/HCV-coinfected, 110 HIV-monoinfected) completed a comprehensive survey assessing ART adherence and its potential correlates. Medical chart extraction identified clinical factors, including liver enzymes. Results demonstrated that ART adherence did not differ by HCV status, with 83.7% of coinfected patients and 82.4% of monoinfected patients reporting optimal (i.e., ≥95%) adherence during a four-day recall period (p = .809). Multivariable logistic regression demonstrated that regardless of HCV status, optimal ART adherence was associated with experiencing fewer adherence-related behavioral skills barriers (AOR = 0.56; 95%CI = 0.43-0.73), lower likelihood of problematic drinking (AOR = 0.15; 95%CI = 0.04-0.67), and lower likelihood of methamphetamine use (AOR = 0.14; 95%CI = 0.03-0.69). However, among HIV/HCV-coinfected patients, optimal adherence was additionally associated with experiencing fewer ART adherence-related motivational barriers (AOR = 0.23; 95%CI = 0.08-0.62) and lower likelihood of depression (AOR = 0.06; 95%CI = 0.00-0.84). Findings suggest that although HIV/HCV-coinfected patients may face additional, distinct barriers to ART adherence, levels of adherence commensurate with those demonstrated by HIV-monoinfected patients might be achievable if these barriers are addressed.
Collapse
Affiliation(s)
- Paul A Shuper
- a Centre for Addiction and Mental Health , Toronto , Canada.,b Dalla Lana School of Public Health , University of Toronto , Toronto , Canada
| | | | - Hyacinth Irving
- c Centre for Management of Technology & Entrepreneurship , University of Toronto , Toronto , Canada
| | | | | | - Mona Loutfy
- b Dalla Lana School of Public Health , University of Toronto , Toronto , Canada.,d Maple Leaf Medical Clinic , Toronto , Canada.,e Women's College Hospital , Toronto , Canada.,f Department of Medicine , University of Toronto , Toronto , Canada
| | - Sharon L Walmsley
- f Department of Medicine , University of Toronto , Toronto , Canada.,g Toronto General Hospital, University Health Network , Toronto , Canada
| | - David K H Wong
- g Toronto General Hospital, University Health Network , Toronto , Canada
| | - Jürgen Rehm
- a Centre for Addiction and Mental Health , Toronto , Canada.,b Dalla Lana School of Public Health , University of Toronto , Toronto , Canada.,g Toronto General Hospital, University Health Network , Toronto , Canada.,h Department of Psychiatry , University of Toronto , Toronto , Canada.,i TU Dresden, Institute for Clinical Psychology and Psychotherapy , Dresden , Germany.,j Department of Community Health and Institute of Medical Science , University of Toronto , Toronto , Canada
| |
Collapse
|
33
|
Hammond ER, Lai S, Wright CM, Treisman GJ. Cocaine Use May be Associated with Increased Depression in Persons Infected with HIV. AIDS Behav 2016; 20:345-52. [PMID: 26370100 DOI: 10.1007/s10461-015-1187-7] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
HIV infection, depression, and cocaine use are independently associated with increased inflammatory signal production. There is increasing evidence about the role of inflammation in depression. In HIV disease, cocaine use may increase disease progression as well as alter T cell functioning resulting in cytokine activation and thereby increasing susceptibility to depression. We examined the association between cocaine use and depression among 447 African American persons infected with HIV who were frequent cocaine users or non-users, enrolled in an observational study in Baltimore, Maryland, between August 2003 and December 2012. The overall prevalence of depression was 40.9 % (183 of 447) participants. Among persons who were depressed, the prevalence of cocaine use was 81.4 % (149 of 183), compared to 69.3 % among persons who were not depressed (183 of 264), P = 0.004. Cocaine use was associated with nearly twofold increased odds of depression, unadjusted odds ratio (OR) 1.94, (95 % CI 1.23, 3.06); P = 0.004, compared to never using cocaine, and OR 1.02, (95 % CI 1.10, 1.05); P = 0.04 in adjusted analysis. A dose-response relationship between increasing duration of cocaine use and depression was observed. Frequency and duration of cocaine use may be associated with depression. We speculate that depression among cocaine users with HIV may involve an inflammatory component that needs further examination.
Collapse
Affiliation(s)
- Edward R Hammond
- Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Meyer 119 Psychiatry, 600 North Wolfe Street, Baltimore, MD, 21287 7119, USA
| | - Shenghan Lai
- Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Carolyn M Wright
- Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Meyer 119 Psychiatry, 600 North Wolfe Street, Baltimore, MD, 21287 7119, USA
| | - Glenn J Treisman
- Department of Psychiatry and Behavioral Science, Johns Hopkins University School of Medicine, Meyer 119 Psychiatry, 600 North Wolfe Street, Baltimore, MD, 21287 7119, USA.
| |
Collapse
|
34
|
Ogbonnaya A, Manafa P, Chucks E, Okeke K, Alo M, Godwin O. The prevalence of diabetes mellitus in human immunodeficiency virus seropositive subjects co-infected with mycobacterium tuberculosis. ACTA ACUST UNITED AC 2015. [DOI: 10.5897/jahr2015.0310] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
|
35
|
White JR, Chang CCH, So-Armah KA, Stewart JC, Gupta SK, Butt AA, Gibert CL, Rimland D, Rodriguez-Barradas MC, Leaf DA, Bedimo RJ, Gottdiener JS, Kop WJ, Gottlieb SS, Budoff MJ, Khambaty T, Tindle HA, Justice AC, Freiberg MS. Depression and human immunodeficiency virus infection are risk factors for incident heart failure among veterans: Veterans Aging Cohort Study. Circulation 2015; 132:1630-8. [PMID: 26358261 DOI: 10.1161/circulationaha.114.014443] [Citation(s) in RCA: 49] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/03/2014] [Accepted: 08/03/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Both HIV and depression are associated with increased heart failure (HF) risk. Depression, a common comorbidity, may further increase the risk of HF among adults with HIV infection (HIV+). We assessed the association between HIV, depression, and incident HF. METHODS AND RESULTS Veterans Aging Cohort Study (VACS) participants free from cardiovascular disease at baseline (n=81 427: 26 908 HIV+, 54 519 without HIV [HIV-]) were categorized into 4 groups: HIV- without major depressive disorder (MDD) [reference], HIV- with MDD, HIV+ without MDD, and HIV+ with MDD. International Classification of Diseases, Ninth Revision codes from medical records were used to determine MDD and the primary outcome, HF. After 5.8 years of follow-up, HF rates per 1000 person-years were highest among HIV+ participants with MDD (9.32; 95% confidence interval [CI], 8.20-10.6). In Cox proportional hazards models, HIV+ participants with MDD had a significantly higher risk of HF (adjusted hazard ratio, 1.68; 95% CI, 1.45-1.95) compared with HIV- participants without MDD. MDD was associated with HF in separate fully adjusted models for HIV- and HIV+ participants (adjusted hazard ratio, 1.21; 95% CI, 1.06-1.37; and adjusted hazard ratio, 1.29; 95% CI, 1.11-1.51, respectively). Among those with MDD, baseline antidepressant use was associated with lower risk of incident HF events (adjusted hazard ratio, 0.76; 95% CI, 0.58-0.99). CONCLUSIONS Our study is the first to suggest that MDD is an independent risk factor for HF in HIV+ adults. These results reinforce the importance of identifying and managing MDD among HIV+ patients. Future studies must clarify mechanisms linking HIV, MDD, antidepressants, and HF and identify interventions to reduce HF morbidity and mortality in those with both HIV and MDD.
Collapse
Affiliation(s)
- Jessica R White
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Chung-Chou H Chang
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Kaku A So-Armah
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Jesse C Stewart
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Samir K Gupta
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Adeel A Butt
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Cynthia L Gibert
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - David Rimland
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Maria C Rodriguez-Barradas
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - David A Leaf
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Roger J Bedimo
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - John S Gottdiener
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Willem J Kop
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Stephen S Gottlieb
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Matthew J Budoff
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Tasneem Khambaty
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Hilary A Tindle
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Amy C Justice
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.)
| | - Matthew S Freiberg
- From Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, PA (J.R.W.); Department of Medicine, University of Pittsburgh School of Medicine, PA (C.-C.H.C.); Department of Medicine, Boston University, MA (K.A.S.-A.); Department of Psychology, Indiana University-Purdue University Indianapolis (J.C.S., T.K.); Department of Medicine, Indiana University School of Medicine, Indianapolis (S.K.G.); Hamad Healthcare Quality Institute, Doha, Qatar (A.A.B.); Hamad Medical Corporation, Doha, Qatar (A.A.B.); VA Medical Center, Washington, DC (C.L.G.); Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA (D.R.); Atlanta VA Medical Center, Decatur, GA (D.R.); Infectious Diseases Section, Michael E. DeBakey VAMC and Department of Medicine, Baylor College of Medicine, Houston, TX (M.C.R.-B.); UCLA School of Medicine and Division of General Medicine, Greater Los Angeles VA Healthcare System, CA (D.A.L.); Department of Medicine, VA North Texas Health Care System, Dallas (R.J.B.); Division of Cardiology, University of Maryland Medical Center, Baltimore (J.S.G.); Department of Medical and Clinical Psychology, Tilburg University, The Netherlands (W.J.K.); Department of Medicine, University of Maryland School of Medicine, Baltimore (S.S.G.); Los Angeles Biomedical Research Institute, Torrance, CA (M.J.B.); Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN (H.T.); Yale University School of Medicine, New Haven, CT (A.C.J.); Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, CT (A.C.J.); and Cardiovascular Medicine Division, Vanderbilt University School of Medicine and Tennessee Valley Healthcare System, Nashville, TN (M.S.F.).
| |
Collapse
|
36
|
Abstract
Human immunodeficiency virus (HIV) is a disease that affects 1 million patients in the United States. Many excellent drug regimens exist that effectively suppress the viral load and improve immune function, but there are consequences of long-term antiviral therapy. In addition, patients with HIV tend to have much higher rates of chronic disease, substance abuse, and cancer. Thus, while expert care in the treatment of HIV remains critical, the skill set of a primary care provider in the prevention, detection, and management of acute and chronic illness is vital to the care of the HIV patient.
Collapse
Affiliation(s)
- Fred R Buckhold
- Internal Medicine Residency Training Program, Division of General Internal Medicine, Department of Medicine, Saint Louis University School of Medicine, 1402 South Grand Boulevard, FDT 14th Floor, Saint Louis, MO 63104, USA.
| |
Collapse
|
37
|
Sico JJ, Chang CCH, So-Armah K, Justice AC, Hylek E, Skanderson M, McGinnis K, Kuller LH, Kraemer KL, Rimland D, Bidwell Goetz M, Butt AA, Rodriguez-Barradas MC, Gibert C, Leaf D, Brown ST, Samet J, Kazis L, Bryant K, Freiberg MS. HIV status and the risk of ischemic stroke among men. Neurology 2015; 84:1933-40. [PMID: 25862803 DOI: 10.1212/wnl.0000000000001560] [Citation(s) in RCA: 139] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Accepted: 01/29/2015] [Indexed: 01/03/2023] Open
Abstract
OBJECTIVE Given conflicting data regarding the association of HIV infection and ischemic stroke risk, we sought to determine whether HIV infection conferred an increased ischemic stroke risk among male veterans. METHODS The Veterans Aging Cohort Study-Virtual Cohort consists of HIV-infected and uninfected veterans in care matched (1:2) for age, sex, race/ethnicity, and clinical site. We analyzed data on 76,835 male participants in the Veterans Aging Cohort Study-Virtual Cohort who were free of baseline cardiovascular disease. We assessed demographics, ischemic stroke risk factors, comorbid diseases, substance use, HIV biomarkers, and incidence of ischemic stroke from October 1, 2003, to December 31, 2009. RESULTS During a median follow-up period of 5.9 (interquartile range 3.5-6.6) years, there were 910 stroke events (37.4% HIV-infected). Ischemic stroke rates per 1,000 person-years were higher for HIV-infected (2.79, 95% confidence interval 2.51-3.10) than for uninfected veterans (2.24 [2.06-2.43]) (incidence rate ratio 1.25 [1.09-1.43]; p < 0.01). After adjusting for demographics, ischemic stroke risk factors, comorbid diseases, and substance use, the risk of ischemic stroke was higher among male veterans with HIV infection compared with uninfected veterans (hazard ratio 1.17 [1.01-1.36]; p = 0.04). CONCLUSIONS HIV infection is associated with an increased ischemic stroke risk among HIV-infected compared with demographically and behaviorally similar uninfected male veterans.
Collapse
Affiliation(s)
- Jason J Sico
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN.
| | - Chung-Chou H Chang
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Kaku So-Armah
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Amy C Justice
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Elaine Hylek
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Melissa Skanderson
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Kathleen McGinnis
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Lewis H Kuller
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Kevin L Kraemer
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - David Rimland
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Matthew Bidwell Goetz
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Adeel A Butt
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Maria C Rodriguez-Barradas
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Cynthia Gibert
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - David Leaf
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Sheldon T Brown
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Jeffrey Samet
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Lewis Kazis
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Kendall Bryant
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | - Matthew S Freiberg
- From the VA Connecticut Health Care System (J.J.S., A.C.J., M.S., K.M.), West Haven Veterans Administration Medical Center, West Haven; Yale University School of Medicine (J.J.S., K.S.-A., A.C.J.), New Haven, CT; University of Pittsburgh School of Medicine (C.-C.H.C., K.L.K., A.A.B.); University of Pittsburgh Graduate School of Public Health (C.-C.H.C., L.H.K.), Pittsburgh, PA; Boston Medical Center (E.H.), MA; Emory University School of Medicine and Atlanta Veterans Administration Medical Center (D.R.), Atlanta, GA; David Geffen School of Medicine at UCLA and the VA Greater Los Angeles Health Care System (M.B.G., D.L.), Los Angeles, CA; VA Pittsburgh Health Care System (A.A.B.), Pittsburgh, PA; Michael E. DeBakey Veterans Administration Medical Center and Baylor College of Medicine (M.C.R.-B.), Houston, TX; Washington DC Veterans Administration Medical Center and George Washington University School of Medicine (C.G.), Washington, DC; James J. Peters VA (S.T.B.), Bronx; Mount Sinai School of Medicine (S.T.B.), New York, NY; Boston University School of Medicine (J.S.), MA; Center for the Assessment of Pharmaceutical Practices (L.K.), Department of Health Policy and Management, Boston University School of Public Health; Center for Healthcare Organization and Implementation Research (L.K.), a Center for Innovation, Veterans Administration Medical Center, Bedford, MA; National Institute on Alcohol Abuse and Alcoholism (K.B.), Bethesda, MD; and Vanderbilt University School of Medicine and the Nashville Veterans Affairs Medical Center (M.S.F.), Nashville, TN
| | | |
Collapse
|
38
|
HIV infection, cardiovascular disease risk factor profile, and risk for acute myocardial infarction. J Acquir Immune Defic Syndr 2015; 68:209-16. [PMID: 25588033 DOI: 10.1097/qai.0000000000000419] [Citation(s) in RCA: 161] [Impact Index Per Article: 17.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
BACKGROUND Traditional cardiovascular disease risk factors (CVDRFs) increase the risk of acute myocardial infarction (AMI) among HIV-infected (HIV+) participants. We assessed the association between HIV and incident AMI within CVDRF strata. METHODS Cohort-81,322 participants (33% HIV+) without prevalent CVD from the Veterans Aging Cohort Study Virtual Cohort (prospective study of HIV+ and matched HIV- veterans) participated in this study. Veterans were followed from first clinical encounter on/after April 1, 2003, until AMI/death/last follow-up date (December 31, 2009). Predictors-HIV, CVDRFs (total cholesterol, cholesterol-lowering agents, blood pressure, blood pressure medication, smoking, diabetes) used to create 6 mutually exclusive profiles: all CVDRFs optimal, 1+ nonoptimal CVDRFs, 1+ elevated CVDRFs, and 1, 2, 3+ major CVDRFs. Outcome-Incident AMI [defined using enzyme, electrocardiogram (EKG) clinical data, 410 inpatient ICD-9 (Medicare), and/or death certificates]. Statistics-Cox models adjusted for demographics, comorbidity, and substance use. RESULTS Of note, 858 AMIs (42% HIV+) occurred over 5.9 years (median). Prevalence of optimal cardiac health was <2%. Optimal CVDRF profile was associated with the lowest adjusted AMI rates. Compared with HIV- veterans, AMI rates among HIV+ veterans with similar CVDRF profiles were higher. Compared with HIV- veterans without major CVDRFs, HIV+ veterans without major CVDRFs had a 2-fold increased risk of AMI (HR: 2.0; 95% confidence interval: 1.0 to 3.9; P = 0.044). CONCLUSIONS The prevalence of optimal cardiac health is low in this cohort. Among those without major CVDRFs, HIV+ veterans have twice the AMI risk. Compared with HIV- veterans with high CVDRF burden, AMI rates were still higher in HIV+ veterans. Preventing/reducing CVDRF burden may reduce excess AMI risk among HIV+ people.
Collapse
|
39
|
So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS. HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function. Curr HIV Res 2015; 12:50-9. [PMID: 25034208 DOI: 10.2174/1570162x1201140716101512] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2014] [Revised: 04/17/2014] [Accepted: 06/07/2014] [Indexed: 11/22/2022]
Abstract
BACKGROUND HIV is associated with end-organ diseases of aging via unclear mechanisms. Longitudinally assessing how HIV infection and ART initiation affect biomarkers of end organ function/disease could clarify these mechanisms. We investigated longitudinal changes in clinical biomarkers following 1) HIV infection and 2) ART initiation with evidence of viral suppression. METHODS COHORT Veterans Aging COHORT Study Virtual COHORT (VACS VC). VACS VC is a longitudinal cohort of HIV infected (HIV+) and race-ethnicity, sex, age, and clinical site-matched uninfected Veterans enrolled in the same calendar year. INCLUSION CRITERIA a negative and successively positive (>six months) HIV antibody test. We used Wilcoxon signedrank tests to analyze 1) the effect of HIV infection on lipids, renal, hepatic and hematologic/cardiovascular biomarkers and 2)whether ART initiation with HIV-1 RNA<500 cpm reverts any changes back to pre-HIV levels. RESULTS 422 Veterans had at least 1 biomarker measurement available prior to HIV infection and prior to ART initiation. 297 had at least 1 biomarker measurement available prior to HIV infection and after ART initiation with evidence of viral suppression. Mean age prior to HIV infection was 43 years. HIV infection was associated with reduction in total cholesterol, HDL cholesterol, LDL cholesterol, serum albumin, ALT, platelet count, hemoglobin and elevation of FIB-4 score and triglycerides. These changes occurred without significant changes in BMI. ART initiation (with HIV-1 RNA<500cpm) did not reverse alteration in triglycerides, LDL cholesterol, hemoglobin, or FIB-4 to pre-HIV infection levels. CONCLUSIONS HIV infection is associated with longitudinal changes in serum levels of several biomarkers of end-organ function/disease and mortality. Multiple biomarkers (triglycerides, LDL cholesterol, hemoglobin, and FIB-4 ) remain altered from levels prior to HIV infection levels even following inititiation of ART and evidence of viral suppression. These results give insights into underlying mechanisms of increased risk for aging-related chronic diseases in the context of HIV infection.
Collapse
|
40
|
Butt AA, Yan P, Lo Re V, Rimland D, Goetz MB, Leaf D, Freiberg MS, Klein MB, Justice AC, Sherman KE. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175:178-85. [PMID: 25485735 PMCID: PMC5017246 DOI: 10.1001/jamainternmed.2014.6502] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
IMPORTANCE Knowing the rate of liver fibrosis progression in hepatitis C virus (HCV)-infected persons can help inform patients and providers (clinicians, medical institutions or organizations, and third-party payers) in making treatment decisions. OBJECTIVE To determine the rate and factors associated with liver fibrosis progression and hepatic decompensation in persons after acquiring HCV infection. DESIGN, SETTING, AND PARTICIPANTS Secondary data analysis of persons in the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES), a national Veterans Affairs (VA) database, between 2002 and 2012. Among 610 514 persons in ERCHIVES (half were HCV positive), we identified those with an initial negative and subsequent positive test result for HCV antibody and positive HCV RNA test result (HCV+). Controls had 2 negative HCV antibody test results (HCV-) in a comparable time frame and were matched 1:1 on age (in 5-year blocks), race, and sex. We excluded persons with human immunodeficiency virus, hepatitis B, less than 24 months of follow-up, hepatocellular carcinoma, and cirrhosis at baseline. MAIN OUTCOMES AND MEASURES Progression of liver fibrosis as estimated by the Fibrosis-4 (FIB-4) index; development of cirrhosis, defined by a FIB-4 score greater than 3.5; and development of hepatic decompensation. RESULTS The evaluable data set consisted of 1840 persons who were HCV+ and 1840 HCV- controls. The HCV+ persons were younger and had a lower mean (SD) body mass index (27.39 [5.51] vs 29.49 [6.16]; P < .001), a higher prevalence of alcohol and drug abuse and dependence diagnoses, and higher serum aminotransferase levels, but had a lower prevalence of diabetes and hypertension. Fibrosis progression started early after infection among HCV+ persons and tapered off after 5 years. A total of 452 cirrhosis and 85 hepatic decompensation events were recorded. After 10 years of follow-up, HCV+ persons were more likely to have a diagnosis of cirrhosis compared with HCV- controls (18.4% vs 6.1%). Nine years after diagnosis of cirrhosis, hepatic decompensation events were uncommon but had a higher rate in the HCV+ group (1.79% vs 0.33%). CONCLUSIONS AND RELEVANCE Persons who seroconverted for HCV have a more rapid progression of liver fibrosis and accelerated time to development of cirrhosis after seroconversion compared with HCV- controls. Fibrosis progression occurs early after infection; however, hepatic decompensation is uncommon after diagnosis of cirrhosis.
Collapse
Affiliation(s)
- Adeel A Butt
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania2VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
| | - Peng Yan
- VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
| | - Vincent Lo Re
- Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia
| | - David Rimland
- Department of Medicine, Atlanta VA Medical Center, Decatur, Georgia
| | - Matthew B Goetz
- Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California
| | - David Leaf
- Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California
| | - Matthew S Freiberg
- Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania2VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania
| | - Marina B Klein
- Department of Medicine, McGill University Health Center, Montreal, Canada
| | - Amy C Justice
- VA Connecticut Healthcare System, West Haven8Department of Medicine, Yale University School of Medicine, New Haven, Connecticut
| | - Kenneth E Sherman
- Department of Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio
| | | |
Collapse
|
41
|
Abstract
PURPOSE OF REVIEW The purpose of this review is to consider a patient-centred approach to the care of people living with HIV (PLWH) who have multimorbidity, irrespective of the specific conditions. RECENT FINDINGS Interdisciplinary care to achieve patient-centred care for people with multimorbidity is recognized as important, but the evaluation of models designed to achieve this goal are needed. Key elements of such approaches include patient preferences, interpretation of the evidence, prognosis as a tool to inform patient-centred care, clinical feasibility and optimization of treatment regimens. SUMMARY Developing and evaluating the best models of patient-centred care for PLWH who also have multimorbidity is essential. This challenge represents an opportunity to leverage the lessons learned from the care of people with multimorbidity in general, and vice versa.
Collapse
|
42
|
Race and other risk factors for incident proteinuria in a national cohort of HIV-infected veterans. J Acquir Immune Defic Syndr 2015; 67:145-52. [PMID: 25072613 DOI: 10.1097/qai.0000000000000285] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND Proteinuria in human immunodeficiency virus (HIV)-infected individuals has been associated with poorer outcomes. We examined risk factors associated with the development of proteinuria in a national registry of HIV-infected veterans. METHODS A total of 21,129 HIV-infected veterans of black and white race without preexisting kidney disease were receiving health care in the Veterans' Health Administration (VHA) medical system between 1997 and 2011. Using the VHA electronic record system, we identified kidney-related risk factors (hypertension, diabetes, and cardiovascular disease) and HIV-related risk factors (CD4 lymphocyte count, HIV RNA level, hepatitis C virus, and hepatitis B virus) for developing proteinuria. Proteinuria was defined by 2 consecutive dipstick measures of 1 or higher. The Fine-Gray competing risk model was used to estimate association between clinical variables and incident proteinuria, while accounting for intervening mortality events. RESULTS During follow-up (median = 5.3 years), 7031 patients developed proteinuria. Overall, black race compared with white race was associated with a higher risk of proteinuria {hazard ratio [95% confidence interval (CI)] = 1.51 [1.43 to 1.59]}, but the association was stronger at younger ages (P interaction <0.001). Age-stratified risk of proteinuria for blacks relative to whites was greatest among veterans <30 years [2.19 (1.66 to 2.89)] and the risk diminished with increasing age [1.14 (0.97 to 1.34) for >60 years]. We found the race difference to be stronger for the outcome of 2 or higher proteinuria [2.13 (1.89 to 2.39)]. Both HIV-related and traditional risk factors were also associated with incident proteinuria (P < 0.05). CONCLUSIONS Compared with whites, risk of proteinuria was higher in black veterans with HIV infection, particularly at younger ages. In both races, HIV- and kidney-related risk factors were associated with higher proteinuria risk.
Collapse
|
43
|
Kasthuri A, Mohanakrishnan K, Amsavathani S, Sumathi G. The HIV Associated Type 2 Diabetes. J Glob Infect Dis 2014; 6:196-7. [PMID: 25538462 PMCID: PMC4265839 DOI: 10.4103/0974-777x.145262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Affiliation(s)
- A Kasthuri
- Department of Community Medicine, Sri Muthukumaran Medical College and Research Institue, Mangadu, Chennai, Tamil Nadu, India
| | - K Mohanakrishnan
- Department of Microbiology, Sri Muthukumaran Medical College and Research Institue, Mangadu, Chennai, Tamil Nadu, India
| | - Sk Amsavathani
- Department of Microbiology, Meenakshi Medical College and Research Institute, Enathur, Kanchipuram, Tamil Nadu, India
| | - G Sumathi
- Department of Microbiology, Sri Muthukumaran Medical College and Research Institue, Mangadu, Chennai, Tamil Nadu, India
| |
Collapse
|
44
|
Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, Rimland D, Rodriguez-Barradas MC, Dubrow R, Park LS, Skanderson M, Shiels MS, Gange SJ, Gebo KA, Justice AC. Comparison of risk and age at diagnosis of myocardial infarction, end-stage renal disease, and non-AIDS-defining cancer in HIV-infected versus uninfected adults. Clin Infect Dis 2014; 60:627-38. [PMID: 25362204 DOI: 10.1093/cid/ciu869] [Citation(s) in RCA: 203] [Impact Index Per Article: 20.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND Although it has been shown that human immunodeficiency virus (HIV)-infected adults are at greater risk for aging-associated events, it remains unclear as to whether these events happen at similar, or younger ages, in HIV-infected compared with uninfected adults. The objective of this study was to compare the median age at, and risk of, incident diagnosis of 3 age-associated diseases in HIV-infected and demographically similar uninfected adults. METHODS The study was nested in the clinical prospective Veterans Aging Cohort Study of HIV-infected and demographically matched uninfected veterans, from 1 April 2003 to 31 December 2010. The outcomes were validated diagnoses of myocardial infarction (MI), end-stage renal disease (ESRD), and non-AIDS-defining cancer (NADC). Differences in mean age at, and risk of, diagnosis by HIV status were estimated using multivariate linear regression models and Cox proportional hazards models, respectively. RESULTS A total of 98 687 (31% HIV-infected and 69% uninfected) adults contributed >450 000 person-years and 689 MI, 1135 ESRD, and 4179 NADC incident diagnoses. Mean age at MI (adjusted mean difference, -0.11; 95% confidence interval [CI], -.59 to .37 years) and NADC (adjusted mean difference, -0.10 [95% CI, -.30 to .10] years) did not differ by HIV status. HIV-infected adults were diagnosed with ESRD at an average age of 5.5 months younger than uninfected adults (adjusted mean difference, -0.46 [95% CI, -.86 to -.07] years). HIV-infected adults had a greater risk of all 3 outcomes compared with uninfected adults after accounting for important confounders. CONCLUSIONS HIV-infected adults had a higher risk of these age-associated events, but they occurred at similar ages than those without HIV.
Collapse
Affiliation(s)
| | | | | | | | - Cynthia Gilbert
- Veterans Affairs Medical Center and George Washington University Medical Center, Washington D.C
| | - Krisann K Oursler
- Salem Veterans Affairs Medical Center, Virginia University of Maryland School of Medicine, Baltimore
| | - David Rimland
- Atlanta Veterans Affairs Medical Center and Emory University School of Medicine, Georgia
| | | | - Robert Dubrow
- Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, Connecticut
| | - Lesley S Park
- Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, Connecticut
| | - Melissa Skanderson
- Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, Connecticut
| | - Meredith S Shiels
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland
| | | | | | - Amy C Justice
- Veterans Affairs Connecticut Healthcare System and Yale Schools of Medicine and Public Health, New Haven, Connecticut
| | | |
Collapse
|
45
|
Katsounas A, Rasimas JJ, Schlaak JF, Lempicki RA, Rosenstein DL, Kottilil S. Interferon stimulated exonuclease gene 20 kDa links psychiatric events to distinct hepatitis C virus responses in human immunodeficiency virus positive patients. J Med Virol 2014; 86:1323-31. [PMID: 24782267 PMCID: PMC4114765 DOI: 10.1002/jmv.23956] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/18/2014] [Indexed: 01/02/2023]
Abstract
Hepatitis C Virus (HCV) infection occurs frequently in patients with preexisting mental illness. Treatment for chronic hepatitis C using interferon formulations often increases risk for neuro-psychiatric symptoms. Pegylated-Interferon-α (PegIFN-α) remains crucial for attaining sustained virologic response (SVR); however, PegIFN-α based treatment is associated with psychiatric adverse effects, which require dose reduction and/or interruption. This study's main objective was to identify genes induced by PegIFN-α and expressed in the central nervous system and immune system, which could mediate the development of psychiatric toxicity in association with antiviral outcome. Using peripheral blood mononuclear cells from Human Immunodeficiency Virus (HIV)/HCV co-infected donors (N = 28), DNA microarray analysis was performed and 21 differentially regulated genes were identified in patients with psychiatric toxicity versus those without. Using these 21 expression profiles a two-way-ANOVA was performed to select genes based on antiviral outcome and occurrence of neuro-psychiatric adverse events. Microarray analysis demonstrated that Interferon-stimulated-exonuclease-gene 20 kDa (ISG20) and Interferon-alpha-inducible-protein 27 (IFI27) were the most regulated genes (P < 0.05) between three groups that were built by combining antiviral outcome and neuro-psychiatric toxicity. Validation by bDNA assay confirmed that ISG20 expression levels were significantly associated with these outcomes (P < 0.035). Baseline levels and induction of ISG20 correlated independently with no occurrence of psychiatric adverse events and non-response to therapy (P < 0.001). Among the 21 genes that were associated with psychiatric adverse events and 20 Interferon-inducible genes (IFIGs) used as controls, only ISG20 expression was able to link PegIFN-α related neuro-psychiatric toxicity to distinct HCV-responses in patients co-infected with HIV and HCV in vivo.
Collapse
Affiliation(s)
- Antonios Katsounas
- Department of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
| | - Joseph J. Rasimas
- Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA
| | - Joerg F. Schlaak
- Department of Gastroenterology and Hepatology, University Hospital Essen, Hufelandstrasse 55, 45147 Essen, Germany
| | - Richard A. Lempicki
- Laboratory of Immunopathogenesis and Bioinformatics, SAIC-Frederick, Inc, National Cancer Institute at Frederick, Frederick, MD 21702, USA
| | - Donald L. Rosenstein
- Department of Psychiatry, University of North Carolina at Chapel Hill, NC 27599-7305, USA
| | - Shyam Kottilil
- Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
| |
Collapse
|
46
|
Abstract
PURPOSE OF REVIEW HIV-infected individuals are living longer as a result of effective treatment. Age-related comorbidities now account for the majority of morbidity and mortality among treated HIV-infected adults. Previous findings regarding the age at, and risk of, these comorbidities have been mixed, sparking debate in the field. Discerning potential differences in the occurrence and burden of age-related comorbidities among treated HIV-infected adults as compared with uninfected adults of the same age requires careful selection of the appropriate uninfected comparison group. RECENT FINDINGS The validity of comparisons with HIV-uninfected populations is threatened when differences in demographic, clinical, and lifestyle characteristics between HIV-infected and uninfected adults are not considered. Identifying a pool of HIV-uninfected individuals from existing secondary data resources and employing selection methodologies may be a novel approach to reduce threats to internal validity. Issues related to identifying data sources, understanding inclusion criteria, determining measurement error, and threats to inference are discussed. SUMMARY The development of clinical interventions targeting age-related comorbidities will rely on deriving valid inferences from appropriate comparison groups. The use of secondary data resources and selection methodology to create the appropriate uninfected comparison group is an attractive approach in the setting of finite resources, but are not without limitations.
Collapse
Affiliation(s)
- Cherise Wong
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Keri Althoff
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| | - Stephen J. Gange
- Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
| |
Collapse
|
47
|
Lim JK, Tate JP, Fultz SL, Goulet JL, Conigliaro J, Bryant KJ, Gordon AJ, Gibert C, Rimland D, Goetz MB, Klein MB, Fiellin DA, Justice AC, Lo Re V. Relationship between alcohol use categories and noninvasive markers of advanced hepatic fibrosis in HIV-infected, chronic hepatitis C virus-infected, and uninfected patients. Clin Infect Dis 2014; 58:1449-58. [PMID: 24569533 DOI: 10.1093/cid/ciu097] [Citation(s) in RCA: 67] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND It is unclear if the risk of liver disease associated with different levels of alcohol consumption is higher for patients infected with human immunodeficiency virus (HIV) or chronic hepatitis C virus (HCV). We evaluated associations between alcohol use categories and advanced hepatic fibrosis, by HIV and chronic HCV status. METHODS We performed a cross-sectional study among participants in the Veterans Aging Cohort Study who reported alcohol consumption at enrollment (701 HIV/HCV-coinfected; 1410 HIV-monoinfected; 296 HCV-monoinfected; 1158 HIV/HCV-uninfected). Alcohol use category was determined by the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) questionnaire and alcohol-related diagnoses and was classified as nonhazardous drinking, hazardous/binge drinking, or alcohol-related diagnosis. Advanced hepatic fibrosis was defined by FIB-4 index >3.25. RESULTS Within each HIV/HCV group, the prevalence of advanced hepatic fibrosis increased as alcohol use category increased. For each alcohol use category, advanced hepatic fibrosis was more common among HIV-infected than uninfected (nonhazardous: 6.7% vs 1.4%; hazardous/binge: 9.5% vs 3.0%; alcohol-related diagnosis: 19.0% vs 8.6%; P < .01) and chronic HCV-infected than uninfected (nonhazardous: 13.6% vs 2.5%; hazardous/binge: 18.2% vs 3.1%; alcohol-related diagnosis: 22.1% vs 6.5%; P < .01) participants. Strong associations with advanced hepatic fibrosis (adjusted odds ratio [95% confidence interval]) were observed among HIV/HCV-coinfected patients with nonhazardous drinking (14.2 [5.91-34.0]), hazardous/binge drinking (18.9 [7.98-44.8]), and alcohol-related diagnoses (25.2 [10.6-59.7]) compared with uninfected nonhazardous drinkers. CONCLUSIONS Advanced hepatic fibrosis was present at low levels of alcohol consumption, increased with higher alcohol use categories, and was more prevalent among HIV-infected and chronic HCV-infected patients than uninfected individuals. All alcohol use categories were strongly associated with advanced hepatic fibrosis in HIV/HCV-coinfected patients.
Collapse
Affiliation(s)
- Joseph K Lim
- Veterans Affairs (VA) Connecticut Healthcare System, West Haven
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Armah KA, Chang CCH, Baker JV, Ramachandran VS, Budoff MJ, Crane HM, Gibert CL, Goetz MB, Leaf DA, McGinnis KA, Oursler KK, Rimland D, Rodriguez-Barradas MC, Sico JJ, Warner AL, Hsue PY, Kuller LH, Justice AC, Freiberg MS. Prehypertension, hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans. Clin Infect Dis 2013; 58:121-9. [PMID: 24065316 DOI: 10.1093/cid/cit652] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Compared to uninfected people, human immunodeficiency virus (HIV)-infected individuals may have an increased risk of acute myocardial infarction (AMI). Currently, HIV-infected people are treated to the same blood pressure (BP) goals (<140/90 or <130/80 mm Hg) as their uninfected counterparts. Whether HIV-infected people with elevated BP have excess AMI risk compared to uninfected people is not known. This study examines whether the association between elevated BP and AMI risk differs by HIV status. METHODS The Veterans Aging Cohort Study Virtual Cohort (VACS VC) consists of HIV-infected and -uninfected veterans matched 1:2 on age, sex, race/ethnicity, and clinical site. For this analysis, we analyzed 81 026 people with available BP data from VACS VC, who were free of cardiovascular disease at baseline. BP was the average of the 3 routine outpatient clinical measurements performed closest to baseline (first clinical visit after April 2003). BP categories used in the analyses were based on criteria of the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Analyses were performed using Cox proportional hazards regression. RESULTS Over 5.9 years (median), 860 incident AMIs occurred. Low/high prehypertensive and untreated/treated hypertensive HIV-infected individuals had increased AMI risk compared to uninfected, untreated normotensive individuals (hazard ratio [HR], 1.60 [95% confidence interval {CI}, 1.07-2.39]; HR, 1.81 [95% CI, 1.22-2.68]; HR, 2.57 [95% CI, 1.76-3.76]; and HR, 2.76 [95% CI, 1.90-4.02], respectively). CONCLUSIONS HIV, prehypertensive BP, and hypertensive BP were associated with an increased risk of AMI in a cohort of HIV-infected and -uninfected veterans. Future studies should prospectively investigate whether HIV interacts with BP to further increase AMI risk.
Collapse
Affiliation(s)
- Kaku A Armah
- Department of Epidemiology, Graduate School of Public Health
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Freiberg MS, Chang CCH, Kuller LH, Skanderson M, Lowy E, Kraemer KL, Butt AA, Bidwell Goetz M, Leaf D, Oursler KA, Rimland D, Rodriguez Barradas M, Brown S, Gibert C, McGinnis K, Crothers K, Sico J, Crane H, Warner A, Gottlieb S, Gottdiener J, Tracy RP, Budoff M, Watson C, Armah KA, Doebler D, Bryant K, Justice AC. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med 2013; 173:614-22. [PMID: 23459863 PMCID: PMC4766798 DOI: 10.1001/jamainternmed.2013.3728] [Citation(s) in RCA: 996] [Impact Index Per Article: 90.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
IMPORTANCE Whether people infected with human immunodeficiency virus (HIV) are at an increased risk of acute myocardial infarction (AMI) compared with uninfected people is not clear. Without demographically and behaviorally similar uninfected comparators and without uniformly measured clinical data on risk factors and fatal and nonfatal AMI events, any potential association between HIV status and AMI may be confounded. OBJECTIVE To investigate whether HIV is associated with an increased risk of AMI after adjustment for all standard Framingham risk factors among a large cohort of HIV-positive and demographically and behaviorally similar (ie, similar prevalence of smoking, alcohol, and cocaine use) uninfected veterans in care. DESIGN AND SETTING Participants in the Veterans Aging Cohort Study Virtual Cohort from April 1, 2003, through December 31, 2009. PARTICIPANTS After eliminating those with baseline cardiovascular disease, we analyzed data on HIV status, age, sex, race/ethnicity, hypertension, diabetes mellitus, dyslipidemia, smoking, hepatitis C infection, body mass index, renal disease, anemia, substance use, CD4 cell count, HIV-1 RNA, antiretroviral therapy, and incidence of AMI. MAIN OUTCOME MEASURE Acute myocardial infarction. RESULTS We analyzed data on 82 459 participants. During a median follow-up of 5.9 years, there were 871 AMI events. Across 3 decades of age, the mean (95% CI) AMI events per 1000 person-years was consistently and significantly higher for HIV-positive compared with uninfected veterans: for those aged 40 to 49 years, 2.0 (1.6-2.4) vs 1.5 (1.3-1.7); for those aged 50 to 59 years, 3.9 (3.3-4.5) vs 2.2 (1.9-2.5); and for those aged 60 to 69 years, 5.0 (3.8-6.7) vs 3.3 (2.6-4.2) (P < .05 for all). After adjusting for Framingham risk factors, comorbidities, and substance use, HIV-positive veterans had an increased risk of incident AMI compared with uninfected veterans (hazard ratio, 1.48; 95% CI, 1.27-1.72). An excess risk remained among those achieving an HIV-1 RNA level less than 500 copies/mL compared with uninfected veterans in time-updated analyses (hazard ratio, 1.39; 95% CI, 1.17-1.66). CONCLUSIONS AND RELEVANCE Infection with HIV is associated with a 50% increased risk of AMI beyond that explained by recognized risk factors.
Collapse
|
50
|
Buprenorphine for human immunodeficiency virus/hepatitis C virus-coinfected patients: does it serve as a bridge to hepatitis C virus therapy? J Addict Med 2013; 6:179-85. [PMID: 22614935 DOI: 10.1097/adm.0b013e318257377f] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/15/2023]
Abstract
OBJECTIVES Buprenorphine is associated with enhanced human immunodeficiency virus (HIV) treatment outcomes including increased antiretroviral therapy initiation rates, adherence, and CD4 cell counts among HIV-infected opioid-dependent individuals. Buprenorphine facilitates hepatitis C virus (HCV) treatment in opioid-dependent patients with HCV monoinfection. Less is known about buprenorphine's role in HIV/HCV coinfection. METHODS We conducted a retrospective chart review to evaluate HCV care for HIV-infected buprenorphine patients in the first 4 years of buprenorphine's integration into a Rhode Island HIV clinic. RESULTS Sixty-one patients initiated buprenorphine. All had HCV antibody testing; 57 (93%) were antibody-positive. All antibody-positive patients underwent HCV RNA testing; 48 (84%) were RNA-positive. Of these, 15 (31%) were not referred to HCV care. Among chronically infected patients, 3 received HCV treatment after buprenorphine; all had cirrhosis and none achieved viral eradication. At buprenorphine induction, most patients had inadequately controlled HIV infection, with detectable HIV RNA (59%) or CD4 cell count less than or equal to 350/μL (38%). CONCLUSIONS Buprenorphine has shown limited success to date as a bridge to HCV treatment within an HIV clinic. Buprenorphine's stabilization of opioid dependence and HIV disease may permit the use of HCV therapy over time.
Collapse
|